In Vitro and In Vivo Cytotoxicity of Boron Nitride Nanotubes: A Systematic Review

Akish Babu Kakarla and Ing Kong

School of Computing, Engineering and Mathematical Sciences, La Trobe University, Bendigo, VIC 3552, Australia; a.kakarla@latrobe.edu.au
* Correspondence: i.kong@latrobe.edu.au

Abstract: Boron nitride nanotubes (BNNTs) are an exciting class of nanomaterials due to their unique chemical and physical characteristics. In recent decades, BNNTs have gained huge attention in research and development for various applications, including as nano-fillers for composites, semiconductor devices, hydrogen storage, and as an emerging material in biomedical and tissue engineering applications. However, the toxicity of BNNTs is not clear, and the biocompatibility is not proven yet. In this review, the role of BNNTs in biocompatibility studies is assessed in terms of their characteristics: cell viability, proliferation, therapeutic outcomes, and genotoxicity, which are vital elements for their prospective use in biomedical applications. A systematic review was conducted utilising the databases Scopus and Web of Science (WOS) (2008–2022). Additional findings were discovered manually by snowballing the reference lists of appropriate reviews. Only English-language articles were included. Finally, the significant analysis and discussion of the chosen articles are presented.

Keywords: boron nitride nanotubes; toxicity; cytotoxicity; biocompatibility; biomedical; tissue engineering

1. Introduction

The past decade has witnessed the rapid development of nanoscale science and technology that led to the discovery of various interesting elements of boron nitride nanotubes (BNNTs). Since BNNTs were reported theoretically in 1994 [1,2] and produced experimentally in the following year (using an arc discharge method) [3], there has been a lot of interest in the research and development of BNNTs as a counterpart nanomaterial for carbon nanotubes (CNTs). BNNTs are similar in structure to CNTs, being cylindrical rolls in which carbon atoms are altered with boron and nitrogen atoms arranged in a hexagonal lattice (Figure 1) [4]. Consequently, various methods focusing on the synthesis of BNNTs have been developed, such as chemical vapour deposition (CVD) [5], ball milling [6], substitution reactions [7], co-precipitation, and annealing processes [8]. These methods produced various geometric nanotubes, purity, and structures of BNNTs to meet the required physiochemical properties. However, standardised methods to produce high yield and high purity BNNTs is still in early stages [9]. Therefore, the synthesis of BNNTs still appears in literature using different catalyst materials to produce application compatible BNNTs [10,11]. Furthermore, BNNTs are structural analogues of CNTs but possess unique chemical and physical properties. BNNTs are electrical insulation with a wide bandgap (~6.0 eV) [4,12] and the conducting of the tubes is independent of chirality, unlike CNTs [4,12]. In addition, BNNTs possess Young’s modulus up to 1.2 TPa [13] and are stable in air, up to 1100 °C [14]. In comparison, CNTs are chemically stable up to 500 °C in air [12,14]. The thermal conductivity of BNNTs is slightly higher than CNTs (~300 W-mK−1) [12,15] at about ~350 W-mK−1 [12] for a diameter of tube ranging from 30–40 nm [4]. In addition, the high-purity BNNTs possess an optical band gap of ~6.0 eV with the absorption peak at...
~205 nm [12,16]. In addition, it was reported that bending of individual BNNTs can alter the insulating behaviour and act as semiconductors [12,16,17]. Owing to their intriguing physical and chemical properties, BNNTs gained significant interest in various applications such as magnetorheological devices [12], nanoelectronics [18], microelectromechanical systems, space travel [19], optical [20], drug delivery [21], polymer nanocomposite [18], and tissue engineering [18,22].

Despite BNNTs being a promising material for various applications, the hydrophobic nature of pristine BNNTs hindered its exploitation in BNNTs applications. In terms of biomedical applications, the solubility, homogeneity, and stability in aqueous media are vital factors [23]. Therefore, to overcome the challenges, researchers have explored the functionalisation of BNNTs (f-BNNTs) with various organic and inorganic materials to obtain water-soluble BNNTs and to enhance the cellular uptake of BNNTs in biomedical applications [23]. Hence, it was evident that a breakthrough in the synthesis and functionalisation of BNNTs would open doors to employ BNNTs in various biomedical applications. However, the research and development of BNNTs is still in its infancy as regards utilising BNNTs as a mainstream nanomaterial in biomaterial applications. This is because no standardised protocol exists to assess the toxicity and biocompatibility of BNNTs. Considering this, the interaction of BNNTs with various types of cells, tissues, and organs needs to be assessed to identify the toxicity of the material. The adverse effects of foreign materials in clinical applications can impact the normal functions of tissues or organs, which can lead to health issues and ultimately can be lethal to the tissues.

In this systematic review article, information regarding the toxicity or cytotoxicity as well as the biocompatibility of BNNTs with various cell lines and animals is reported. Indeed, the objective of the review is to clarify the biocompatibility and to promote the design of future BNNTs in biological domains as having potential for tissue-engineering applications.

2. Methodology
2.1. Eligibility Criteria

In vitro and in vivo studies that used BNNTs to address toxicity and biocompatibility until February 2022 from Scopus and Web of Science (WOS) databases were included in this review. Included published studies were limited to English language and journal articles only. The search excluded abstracts, reviews, letters, and theses.

2.2. Types of Interventions

Studies that were conducted using BNNTs as the source to investigate cell viability, cytokines, inflammation, genotoxicity, and toxicity effects on animals were included. Studies that used derivates of boron nitride, boron nitride nanospheres, boron nitride nanoribbons,
or boron nitride nanoplates were excluded. Studies discussing density functional theory (DFT) or theoretical BNNT cellular dynamics were also excluded.

2.3. Information Source

A systematic search using Scopus and WOS was performed to identify studies (looking at BNNTs in vivo and in vitro) reporting the outcomes of toxicity, cytokines, and biocompatibility of materials. The keywords that identified the studies are listed below (Table 1). All the selected articles’ bibliographies were screened manually.

**Table 1.** List of keywords to identify the articles in Scopus and WOS.

| Keywords                                                                                                                                                                                                                                                                                                                                                                               |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| “Boron nitride nanotubes” or “bnnts” and “toxicity” or “in vivo” or “in vitro” or “tissue engineering” or “biomedical”) and (limit—to (doctype, “ar”)) and (limit—to (srctype, “j”)) and (limit—to (language, “English”)) and (limit—to (pub stage,” final”)                                                                                                                                                                                                                      |
| “Boron nitride nanotubes” (topic) and “biomedical” (topic) and review articles or proceedings papers or book chapters or early access (exclude—document types) and articles (document types) and English (languages)                                                                                                                                                                                                                                                 |
| “Boron nitride nanotubes” (topic) and “tissue engineering” (topic) and review articles or proceedings papers or book chapters or early access (exclude—document types) and articles (document types) and English (languages)                                                                                                                                                                                                                           |
| “Boron nitride nanotubes” (topic) and “toxicity” (topic) and review articles or proceedings papers or book chapters or early access (exclude—document types) and articles (document types) and English (languages)                                                                                                                                                                                                                           |
| “Boron nitride nanotubes” (topic) and “in vivo” (topic) and review articles or proceedings papers or book chapters or early access (exclude—document types) and articles (document types) and English (languages)                                                                                                                                           |
| “Boron nitride nanotubes” (topic) and “in vitro” (topic) and review articles or proceedings papers or book chapters or early access (exclude—document types) and articles (document types) and English (languages)                                                                                                                                                                                                |

2.4. Data Collection

The obtained articles from search sources were extracted into an Excel spreadsheet, and this was performed using the PRISMA search strategy (Figure 2). Two independent reviewers performed the screening of the articles. Titles and abstracts were screened initially by one reviewer (A.B.K.) using the selection criteria described in Figure 1. Selected studies from the first screening were then screened independently by two reviewers (A.B.K. and I.K.). The full text of the studies was verified independently by the same reviewers (A.B.K. and I.K.) using the same selection criteria. The reviewers discussed differences in opinion until a consensus was reached. Snowballing search from other reviews and selected papers was also conducted to identify additional articles.
Figure 2. PRISMA search strategy.

3. Results
3.1. Study Selection

The process of article selection and data extraction is shown in Figure 1. In the primary search, a total of 284 articles were found from the Scopus and WOS databases. A total of 140 articles were chosen after duplicates were removed. Then, records were screened and irrelevant studies such as simulations and non-toxicity studies (according to the abstracts and titles) were removed, and 65 studies remained. In the next step, the full texts of 65 selected articles were reviewed, and 4 articles were removed. Ultimately, a total of 61 articles were included in this systematic review (Table 2).
Table 2. Summarised correlation between BNNTs geometry, functionalisation, dosage, and time of exposure on various cells and their outcomes.

| Authors and References | Synthesis/ Source of BNNTs | Geometrical Dimensions of BNNTs | Functionalisation/ Composition of BNNTs | Dosage and Time of Exposure | Animal Model/ Cell Line | Physicochemical Characterisation | Biocompatibility and Toxicity Assays | Outcomes |
|------------------------|----------------------------|--------------------------------|----------------------------------------|-----------------------------|--------------------------|--------------------------------|----------------------------------|---------|
| Kakarla et al. [24,25] | Co-precipitation and annealing | Diameter: 70 to 130 nm | Hydroxyl-BNNTs (BNNTs-OH)/BNNTs reinforced alginate and gelatin/BNNTs reinforced alginate hydrogel scaffolds | 0.05 to 0.1 w·v⁻¹%, up to 72 h | HEK 293T | Scanning electron microscopy (SEM), transmission electron microscopy (TEM), Fourier transform spectroscopy (FTIR), mechanical, thermogravimetric analysis (TGA) | Viability: Trypan blue and Ready Probes™ Cell Viability Imaging Kit (blue/green) | Good printability, mechanical strength, and thermal stability with the addition of BNNTs. Minimal toxicity at higher concentrations of BNNTs. |
| Evariste et al. [26] | Commercial BNNTs (B and N > 99.9%) | Diameter: 2 to 14 nm | – | 0, 0.1, 1, and 10 mg L⁻¹; up to 24 h. Larvae were fed twice daily with BNNTs ground aquarium fish food | Xenopus laevis | SEM, TEM, TGA, XRD, and Raman spectroscopy | Micronucleus test, cell cycle analysis, analysis of sequences from gut microbiota survey | The specific surface area of BNNTs was 163 m²·g⁻¹. Micrographs displayed 2 to 10 walls of nanotubes with a mean outer diameter of 6 ± 2.6 nm. BNNTs possessed minor threat to amphibians. |
| Li et al. [27] | Solid-state reaction | – | Folate-conjugated BNNTs and coated with auristatin-phenethylamine (PE) (BNNTs-FA@PE) | 0–100 µg mL⁻¹ | Hep G2 and L02 | TEM, FTIR, ultraviolet-visible (UV-vis) absorption spectroscopy, X-ray photoelectron spectroscopy (XPS), size distribution and zeta potential | CCK-8 assay, cellular uptake, actin staining, in vitro anticancer effects, Annexin V/HTC/propidium iodide (PI), mitochondrial membrane potential, Western blot analysis, detection of Caspase 3/7 activity | The morphology showed bamboo-like shaped nanotubes with diameter of ≈90 nm. BNNTs displayed photoluminescence emission bands at 419, 489, and 594 nm. FTIR analysis displayed BNNTs-FA@PE had absorption bands at 2937–2829 cm⁻¹ and 1250–950 cm⁻¹ related to the methylene bands of PE molecules. No toxicity in both cell lines and significant increase in metabolic and cellular uptake. |
| Li et al. [28] | Solid-state reaction | PE-loaded BNNTs | 0–100 µg mL⁻¹ | Hep G2 Cells | SEM, TEM, Z-potential, FTIR, UV–vis, XPS | Intracellular uptake, lysosomal staining, actin staining, cell viability, flow cytometry, western blot, Caspase-3/7 activity | The morphology images displayed BNNTs bamboo-like structures with good dispersive behaviour. Furthermore, BNNTs showed strong emission bands related to B-N and excellent PL properties in the visible light range. The in vivo analysis displayed good internalisation and stimulated cell apoptosis of BNNTs-PE. |

Note: BNNTs = Boron Nitride Nanotubes; SEM = Scanning Electron Microscopy; TEM = Transmission Electron Microscopy; FTIR = Fourier Transform Infrared Spectroscopy; TGA = Thermogravimetric Analysis; XPS = X-ray Photoelectron Spectroscopy; UV–vis = Ultraviolet–visible; XRD = X-ray Diffraction; Raman = Raman; CCK-8 = Cell Counting Kit–8; PI = Propidium Iodide; Annexin V = Annexin V Conjugated with Fluorescein-5-isothiocyanate; Caspase = Caspase; HEK 293T = Human Embryonic Kidney 293T; Xenopus laevis = African clawed frog; SEM = Scanning Electron Microscopy; TEM = Transmission Electron Microscopy; FTIR = Fourier Transform Infrared Spectroscopy; TGA = Thermogravimetric Analysis; CCK-8 assay = Cell Counting Kit–8 assay; annexin V-Fluorescein isothiocyanate/propidium iodide (Annexin V-FITC/PI) = Annexin V-Conjugated with Fluorescein-5-isothiocyanate/Propidium Iodide; TEM, FTIR, ultraviolet-visible (UV-vis) absorption spectroscopy, X-ray photoelectron spectroscopy (XPS), size distribution and zeta potential = Transmission Electron Microscopy, Fourier Transform Infrared Spectroscopy, Ultraviolet–visible Absorption Spectroscopy, X-ray Photoelectron Spectroscopy, Size Distribution, and Zeta Potential.
### Table 2. Cont.

| Authors and References | Synthesis/ Source of BNNTs | Geometrical Dimensions of BNNTs | Functionalisation/ Composition of BNNTs | Dosage and Time of Exposure | Animal Model/ Cell Line | Physiochemical Characterisation | Biocompatibility and Toxicity Assays | Outcomes |
|------------------------|----------------------------|---------------------------------|----------------------------------------|-----------------------------|--------------------------|-------------------------------|----------------------------------|---------|
| Xin et al. [29]        | Commercial BNNTs that contain 50% BNNTs with 5 nm wide and 200 µm long | Length: 200 µm; diameter: 5 nm | –                                      | 4 or 40 µg; 4 h, 1–7 days, 1–2 months. The mice were fed with BNNT mixed in dispersion media through an oropharyngeal aspiration. | Male C57BL/6 J mice | SEM, TEM, electron paramagnetic response spectra | Lung lavage, BAL cell differentiation, lactic dehydrogenase activity (LDH), BAL fluid protein analysis, lymphocyte phenotypic quantification, mediastinal lymph node and spleen analysis, white blood cell differentiation, histopathology, macrophage uptake, pulmonary clearance, RNA isolation and gene expression | The micrographic analysis of BNNTs showed an ideal length of nanotubes. The specific surface area of BNNTs was 182.6 ± 2.4 m² g⁻¹ with the density of 0.03 g cm⁻³. Only a higher dosage of BNNTs caused the inflammation and a lower dose did not show any effects in the lung. |
| Lee et al. [21]        | Commercial BNNTs | – | Purified BNNTs | 0–100 µg | CHO-K1 and 3T3-L1 | SEM, XRD, dispersion stability | Cell viability, drug delivery | The SEM and dispersion stability analysis confirmed the nanotubes in tubular structures with stable dispersion in aqueous media. The XRD analysis observed the hexagonal lattice of B–N in BNNTs. Purified BNNTs showed lower cytotoxic at a higher dosage and efficiently carried the drugs than as synthesised BNNTs. |
| Pasquale et al. [30]   | BNNTs loaded with dox and coated with cell membranes (CM) (Dox-CM-BNNTs) | – | U87 | 25, 50, 100, and 200 µg mL⁻¹; up to 72 h | TEM, FTIR, size distribution, zeta potential, TGA, dynamic light scattering (DLS), bicinchoninic acid assay | Cell uptake mechanism, cell viability | | The morphology of BNNTs coated with CM was not precise due to low thickness. The FTIR confirmed that BNNTs coated with CM with presence of peaks related to amino acids of CM proteins. The TGA analyses indicated that the total weight loss of CM-BNNTs was 20%. DLS analysis indicated that negative Z-potential related to stable colloidal solution. Dox-CM-BNNTs and free drug were able to substantially decline the cell viability compared to non-treated controls and BNNT controls. |
Table 2. Cont.

| Authors and References | Synthesis/ Source of BNNTs | Geometrical Dimensions of BNNTs | Functionalisation/ Composition of BNNTs | Dosage and Time of Exposure | Animal Model/ Cell Line | Physiochemical Characterisation | Biocompatibility and Toxicity Assays | Outcomes |
|------------------------|----------------------------|--------------------------------|----------------------------------------|-----------------------------|------------------------|-------------------------------|--------------------------------------|----------|
| Marcos da Silva et al. [31] | Chemical vapor deposition (CVD) | ~ | BNNTs doped in situ with samarium (Sm) and gadolinium (Gd) (SmBO$_3$-BNNTs and GdBO$_3$-BNNTs) | 10 and 50 µg mL$^{-1}$; up to 24 h | HDF and Sarcoma osteogenic (SAOS-2) | XPS, FTIR, SEM, TEM, X-ray fluorescence spectroscopy (XRF), electron energy loss spectroscopy (EELS), vibrational sample magnetometry (VSM), neutron activation | MTT assay, Calcein/Hoechst assay | SEM and TEM images confirmed that the BNNTs were successfully modified with Sm and Gd with uniform distribution on their surfaces. The XPS and EELS analysis further confirmed the presence of Sm and Gd in the BNNTs. In addition, VSM analysis stated that coated BNNTs exhibited magnetic properties. 50 µg mL$^{-1}$ of GdBO$_3$-BNNTs suggested low biocompatibility with fibroblasts (50% of cell viability), but high biocompatibility with SAOS-2 cells (80% of cell viability). |
| Ferreira et al. [32] | CVD | Diameter: 30 nm; length: 1 µm | BNNT with the CREKA peptide/99mTc-BNNT-CREKA | 100 µL; 1, 4 and 8 h | 4T1 tumour cells | SEM, TEM, TGA, zeta potential, FTIR | Biodistribution histopathological and blood clearance analysis; fluorescence microscopy cell images | The SEM and TEM micrographs revealed several nanotubes with ≈10 nm outer wall thickness. BNNTs and coated BNNTs showed good thermal stability. FTIR analysis showed B-N stretching vibrations and additional C—H, O—H and O—C bands in coated BNNTs. BNNTs-CREKA as an effective material for targeting the primary tumour tissues and metastatic tumour sites. |
| Ferreira et al. [33] | Commercial BNNTs | | BNNTs incorporated with alkyl trimethyl ammonium bromide (ATAB) | 0 to 0.2 wt%; up to 72 h | HaCaT | FTIR (degree of conversion (DC) analysis), microhardness, contact angle, mineral deposition | Cytotoxicity assay and antibacterial assay | No DC was noted in the samples. The contact angle was higher for functionalised BNNTs. The mineral deposition analysis was displayed higher peak intensities in BNNTs-ATAB. No significant cell viability reduction was observed in the BNNTs-ATAB compared with control groups (90%). |
| Authors and References | Synthesis/ Source of BNNTs | Geometrical Dimensions of BNNTs | Functionalisation/ Composition of BNNTs | Dosage and Time of Exposure | Animal Model/ Cell Line | Physiochemical Characterisation | Biocompatibility and Toxicity Assays | Outcomes |
|------------------------|-----------------------------|--------------------------------|---------------------------------------|-----------------------------|------------------------|--------------------------------|----------------------------------|---------|
| Bohns [34]             | Commercial BNNTs            | Length: 200 µm                 | BNNTs reinforced resin-based dental sealants (RBSs) | 0.1 and 0.2 wt%             | Pulp fibroblasts and human keratinocytes | FTIR, tensile strength, contact angle, surface roughness, colour assessment, Mineral deposition | Sulforhodamine B (SRB) cytotoxicity assay | No evidence of DC in the BNNTs-RBSs. The additions of BNNTs to RBSs did not show a significant difference in tensile strength from RBSs. The contact angle values were adequate even though the incorporation of nanotubes. Lower surface energy was noticed for BNNTs comprising RBSs. BNNTs at 0.1 and 0.2 wt% in RBSs did not show any cytotoxicity effects. |
| Çal [35]               | Commercial BNNTs            | Diameter: 5 nm                 | BNNTs incorporated with curcumin        | 10–300 µg mL⁻¹; up to 24 h | HeLa, V79 and CD34⁺ | TEM, zeta potential | MTT assay, comet assay | The TEM images showed the BNNTs with micrometres length and Z-potential with positive z signals for curcumin in the BNNTs. BNNTs and BNNTs-curcumin showed minimal toxicity in all cell lines |
| Ricotti et al. [36]    | Annealing                   | –                              | Glycol-chitosan (GC)-BNNTs              | 10 µg mL⁻¹; for 24 h        | HDF and C2C12         | Focused ion beam (FIB), ICP-MS, EELS | Quantitative real-time polymerase chain reaction (qRT-PCR), cytokine measurements, calcium transients imaging | FIB images revealed evenly dispersed GC-BNNTs in cell culture medium. The ICP-MS showed highest content of boron in cells treated with GC-BNNTs. EEL spectrum confirmed the presence of GC-BNNTs in sections of C2C12 cells. BNNTs were internalised on the top layer of cells and localised inside C2C12 cells, while no particles were internalised by the HDF cells. In addition, BNNTs stimulate cell differentiation at both gene and protein levels. |
| Augustine et al. [37]  | Thermal plasma              | –                              | –                                     | 5 to 10 mg of BNNT in 20 mL glass scintillation vial | NB4, HepG2, U87, and A549 | AFM, and probe sonication | WST-8, MTT and monitoring beating behaviour of cardiomyocytes | The AFM analysis of BNNTs displayed that the tubes were ≈300 to 500 nm in length with 2 to 3 nm in height. While after probe sonication, the length of nanotubes decreased to 191.9 ± 5.2 nm. BNNTs displayed cytotoxic to the cells measured through AFM-based cardiomyocyte assay. |
| Authors and References | Synthesis/ Source of BNNTs | Geometrical Dimensions of BNNTs | Functionalisation/ Composition of BNNTs | Dosage and Time of Exposure | Animal Model/ Cell Line | Physiochemical Characterisation | Biocompatibility and Toxicity Assays | Outcomes |
|------------------------|---------------------------|--------------------------------|----------------------------------------|-----------------------------|-------------------------|-------------------------------|-------------------------------------|---------|
| Poudel et al. [38]     | Commercial BNNTs          | 20–30 µm thickness             | Polyvinylidene fluoride (PVDF) and the trifluoroethylene (TrFE) reinforced with BNNTs (PVDF-TrFE-BNNTs) | 10 days                     | Human tendon derived cells | DSC, FTIR, differential scanning calorimetry (DSC), tensile analysis, electrical poling, quasi-static measurement of piezoelectric coefficient | Fibronectin functionalisation, live/dead assay, cell proliferation assay | Addition of BNNTs was evident in enhancing mechanical properties, melting and crystallisation temperatures, and crystallinity. PVDF-TrFE-BNNTs nanocomposite displayed enhanced cell attachment and proliferation compared to pure PVDF-TrFE. |
| Genchi et al. [39]     | Pressurised vapor/condenser (PVC) | –                              | PVDF-TrFE-BNNTs                        | –                           | Saos-2                  | SEM, TEM, AFM, piezo response, piezoelectric transduction, numerical simulation | Cell differentiation, cell stimulation, alizarin red and collagen staining, quantitative real-time reverse transcriptase polymerase chain reaction | The micrographs of BNNTs revealed bundles of nanotube ranging up to µm in length. AFM topographic maps of the PVDF-TrFE-BNNTs showed ~30 nm of mean surface roughness with good piezo electric properties. The piezoelectric films of PVDF-TrFE-BNNTs indicated increased cell differentiation. |
| Demir et al. [40]      | Commercial BNNTs          | Average diameter 239.7 ± 6.48 nm | –                                      | 0.0003, 0.003, 0.027, 0.135, and 0.270 mg g⁻¹ | Drosophila (D) melanogaster adults and larvae | SEM, TEM, DLS, laser doppler velocimetry (LDV) | Endotoxin assay, drosophila strain, exposure, and toxicity, hemocytes collection, ROS, gene expression changes, genotoxicity, antigenotoxicity, comet assay | SEM and TEM images of BNNTs revealed that the average nanotubes length was 245 ± 65.72 nm. The DLS and LDV analysis showed lower zeta potential that indicated the propensity of BNNTs to aggregates. BNNTs treated larvae increased the genotoxicity and antigenotoxicity. |
| Degrazia et al. [41]   | PVC                       | –                              | BNNTs incorporated with bisphenol A glycolate dimethacrylate (BisGMA) and hydroxystyrol methacrylate | 0.05, 0.075, 0.1 and 0.15 wt% | Fibroblasts              | FTIR, contact angle, micro tensile bond strength, failure pattern analysis | Cytotoxicity sulforhodamine B (SRB) colorimetric assay, cell viability | The successful incorporation of 0.1 wt% BNNTs into adhesive resin increased the tensile and longer stability. BNNTs treated with cells did not show any cytotoxicity. |
| Authors and References | Synthesis/Source of BNNTs | Geometrical Dimensions of BNNTs | Functionalisation/Composition of BNNTs | Dosage and Time of Exposure | Animal Model/Cell Line | Physiochemical Characterisation | Biocompatibility and Toxicity Assays | Outcomes |
|------------------------|--------------------------|-------------------------------|---------------------------------------|-----------------------------|-----------------------|--------------------------------|-------------------------------------|---------|
| Ferreira et al. [42]   | CVD                      | –                             | BNNTs-OH–ferric oxide (Fe₃O₄)          | 0–2 µg mL⁻¹; 48 h            | HeLa                  | XRD, TEM, XPS, vibrating sample magnetometer (VSM) | WST-8 and CCK-8 assay, internalisation tests, magneto hyperthermia assay, cell death assay (calcein-AM and PI), cell imaging | Micrograph imaging revealed a bundle of nanotubes with tube like structures. The XPS analysis showed that BNNTs consisted mostly of B and N atoms. Magnetic measurements displayed that coercivity and magnetisation were not agitated with the addition of BNNTs. The results showed excellent viability of cells treated with OH-BNNT-Fe₃O₄ and validated the internalisation capability of BNNTs by the cells. |
| Ferreira et al. [43]   | CVD                      | –                             | BNNTs-OH covered with radioactive C-39 detectors | 0–200 µg mL⁻¹; up to 48 h | HeLa                  | SEM, FTIR, XRD                                      | WST-8, CCK-8, performance test, cells irradiation | The outcomes showed no evidence of changes in crystallinity of the material and intense solid B-N bonds. No substantial differences after irradiation in the microstructures of the BNNTs compared to pure BNNTs. BNNTs had appropriate cell viability and that irradiation with a suitable flux of thermal neutron without adverse damage in the cells. |
| Ponraj et al. [44]     | Ball milling             | –                             | Gold nanoparticles functionalised on BNNTs and loaded with dox | 30, 60, and 90 µL           | DU145                 | TEM, XPS                                        | Cyquant assay                             | Micrographs images showed long and medium BNNTs. XPS analysis displayed the BNNT surface with oxygen rate from 8 to 27.4%. The dox loaded BNNTs killed ~99% of cancer cells, which resulted in good drug carrier for cancer treatment. |
| Kodali et al. [45]     | Commercial BNNTs        | Length:0.6 to 1.6 µm          | –                                     | 0–100 µg mL⁻¹               | THP-1 cells, NLRP3 and c57BL/6J mice | SEM, TEM, DLS                                    | ROS, high content epifluorescence microscopy, lysosomal permeabilisation, cytokine analysis, cathepsin B and caspase 1 activity inside the cells, phagocytosis and lipopolysaccharide (LPS) functional assays | The morphology images showed BNNTs with a diameter ranging from 13–23 nm observed with a minimum agglomerate rate. BNNTs showed acute inflammation and toxicity both in vitro and in vivo condition. |
| Authors and References | Synthesis/ Source of BNNTs | Geometrical Dimensions of BNNTs | Functionalisation/ Composition of BNNTs | Dosage and Time of Exposure | Animal Model/ Cell Line | Physiochemical Characterisation | Biocompatibility and Toxicity Assays | Outcomes |
|------------------------|-----------------------------|--------------------------------|--------------------------------------|-----------------------------|------------------------|-------------------------------|--------------------------------------|---------|
| Sen et al. [46]        | CVD                         | –                             | Hydroxylated BNNTs modified with oligonucleotides (BNNTs-OH-oligo) and further doped with morpholino | –                           | MDA-MB-231-luc2          | TEM, FTIR, agarose gel electrophoresis | Cell viability assay, luciferase activity | FTIR spectrum showed the B-N and –OH bands in the BNNTs and TEM images displayed some damaged nanotubes due to hydroxylation. The luciferase activity decreased when MDA-MB-231-luc2 cells were incubated with morpholino/oligo-BNNTs. The cell viability results almost similar to control. |
| Farshid et al. [47]    | Commercial BNNTs            | Length 1–2 μm and diameter ~100 nm | BNNTs reinforced propylene fumarate (PPF-BNNTs) nanocomposites | 24 h                        | MC3T3                  | TEM, X-ray spectroscopy, Raman spectroscopy, sol-fraction analysis, compressive test | Presto Blue® assay, LDH, Calcein-AM staining, osmolarity of degradation, cell attachment and spreading | BNNTs displayed a tubular morphology with a diameter of 100 nm and length of 1–2 μm. The spectroscopy analysis showed good bands of B-N. Furthermore, the compressive modulus increased up to 6% with the incorporation of BNNTs in PPF. BNNTs reinforced polymer nanocomposite was non-cytotoxic. |
| Emanet et al. [48]     | CVD                         | Length: 5 μm; and diameter 10 nm | BNNTs-OH reinforced chitosan | Up to 7 days            | HDF                    | SEM, TEM, fluorescent microscopy, mechanical, in vitro biodegradation | WST-1 colorimetric assay, cell proliferation and adhesion | The micrograph images showed large pores in the BNNTs-chitosan scaffolds. FTIR spectra of the BNNTs showed the -OH and B-N bands of the modified BNNTs BNNT-OH-chitosan scaffolds showed enhanced mechanical strength and reduced water absorption. The cell viability results showed that increase in viability rate over the incubation time in BNNTs-OH reinforced chitosan |
| Rocca et al. [49]      | CVD                         | Length: 2 μm and diameter ~50 nm | Pectin coated BNNTs (P-BNNTs) | 0 to 50 μg mL⁻¹; up to 24 h | RAW 264.7              | SEM, TEM, zeta potential | WST-1 assay, quant-iT PicoGreen dsDNA assay, reactive oxygen species, annexin V-FITC apoptosis detection, cytokine detection, qRT-PCR | The results indicated that pectin coated BNNTs significantly improved the dispersibility of BNNTs. Furthermore, the micrograph analysis showed that 65% of cells positively internalised of P-BNNTs without any effects BNNTs with pectin did not show any adverse effects on cells. |
| Authors and References | Synthesis/Source of BNNTs | Geometrical Dimensions of BNNTs | Functionalisation/Composition of BNNTs | Dosage and Time of Exposure | Animal Model/Cell Line | Physiochemical Characterisation | Biocompatibility and Toxicity Assays Outcomes |
|------------------------|---------------------------|--------------------------------|----------------------------------------|----------------------------|------------------------|-------------------------------|------------------------------------------|
| Niskanen et al. [50]   | Boron oxide-assisted chemical vapor deposition (BOCVD) | Length: 15 µm | BNNTs modified with isopropanol, glycine coated BNNTs loaded with curcumin | 0–50 µg mL⁻¹; up to 72 h | N9 murine microglia | TEM | Confocal and non-confocal fluorescence microscopy, cellular uptake, cell viability, mitochondrial metabolic activity assay, Griess test, ELISA assay | The micrograph analysis reported that BNNTs were successfully coated with glycine and loaded with curcumin. However, the sonication resulted in shortened length and damaged some nanotubes. Non-cytotoxic. |
| Sen et al. [51]        | CVD                       | –                             | BNNTs-OH reinforced gelatine and glucose | 7 days | HDF | SEM, TEM, contact angle, tensile test, in vitro biodegradation | Cell viability, adhesion, and proliferation | The results indicated that the biodegradation amount of the scaffolds was slower with the incorporation of BNNTs. The SEM and fluorescence microscopy images showed that the BNNTs positively impacted cell adhesion and proliferation. The cells retained their own morphology and increased the proliferation rate with inclusion of BNNTs. |
| Li et al. [52]         | CVD                       | Length: 1–2 µm; diameter: 80 nm | –                                      | 0–50 µg mL⁻¹; up to 14 days | MSCs | SEM, TEM, AFM, protein absorption | Cell viability | The SEM and TEM images of BNNTs showed the nanotubes of 1–2 µm length. The AFM analysis confirmed that BNNTs were uniformly distributed on the surface of piranha solution treated substrate. The protein absorption measurement indicated highest absorption ability with BNNTs on the substrate. BNNTs showed good biocompatibility with MSCs. |
| Diez-Pascual et al. [53] | CVD                       | –                             | Polyethylene glycol grafted BNNTs reinforced poly(propylene fumarate) (PEG-g-BNNTs-PPF) | 0, 0.1, 0.5, 1.0, 2.0, 4.0 wt%; up to 24 h | HDF | FESEM, TGA, water uptake, tensile tests, antibacterial action, biodegradability, protein absorption, tribological analysis | Cell viability (alamarBlue assay) | SEM micrographs displayed a random and uniform dispersion of the PEG-g-BNNTs in the PPF. The degree of hydrophilicity, water absorption, protein absorption and biodegradability enhanced with increasing PEG-g-BNNTs content. In addition, the BNNTs nanocomposites did not show toxicity for the adhesion and growth of HDF cells. |
| Authors and References | Synthesis/ Source of BNNTs | Geometrical Dimensions of BNNTs | Functionalisation/ Composition of BNNTs | Dosage and Time of Exposure | Animal Model/ Cell Line | Physiochemical Characterisation | Biocompatibility and Toxicity Assays | Outcomes |
|------------------------|-----------------------------|---------------------------------|---------------------------------------|--------------------------|-------------------------|-----------------------------|-------------------------------------|----------|
| Fernandez-Yague et al. [54] | PVC | – | Polydopamine (PD) functionalised BNNTs (PD-BNNTs) | 1, 10, 30 µg mL⁻¹; up to 72 h | Osteoblasts | XPS, TEM, DLS | Live/dead assay | The TEM images indicated that the BNNTs were successfully coated with PD, and XPS analysis confirmed the presence of elemental composition of PD in BNNTs varied from BNNTs. The dispersion of PD-BNNTs in media without any precipitation was confirmed with DLS. The PD-BNNTs do not show any cytotoxic effects on cells. |
| Emanet et al. [55] | CVD | – | BNNTs-OH combined with glucose, lactose and starch | 5 to 200 µg mL⁻¹; up to 3 days | HDF and A549 | TEM, FTIR, TGA, protein interaction | Cellular uptake, ROS, cell viability, genotoxicity assay | The TEM images displayed the smooth nanotubes, and FTIR analysis confirmed the -OH and B-N bands in modified BNNTs. Furthermore, the results indicated no negative of cells treated with BNNTs. |
| Danti et al. [56] | – | – | BNNTs functionalised myoblast/microfibre mesh constructs | 108 h | C2C12 | SEM | Cellular viability, protein expression, spatial distribution, 4′,6-diamidino-2-phenylindole staining, phalloidin-Alexa 488 staining | Micrographs displayed the myotubes on the surface of the BNNTs. The results stated that cells were able to differentiate and to internalise upon treating with BNNTs. |
| Salvetti et al. [57] | CVD | Length: 10 µm; diameter: 10–80 nm | Gum Arabic coated BNNTs (GA – BNNTs) | 100 or 200 µg g⁻¹; 4 and 24 h; Injected GA-BNNTs | Planarians | TEM, morphometric analysis, Inductive coupled plasma (ICP)-AES | DNA diffusion and comet assay, propidium iodide/JC1 staining, qRT-PCR, phototactic assay, analysis of mitosis | The morphological analysis demonstrated micrometres length of BNNTs, and there were no abnormalities observed after injecting GA-BNNTs into planarians. BNNTs did not induce DNA damage or apoptosis or does not show harmful effects on planarian stem cells. |
| Ferreira et al. [58] | CVD | Length=1 µm | BNNTs functionalised with folic acid (FA-BNNTs) | 0–50 µg mL⁻¹; 1 and 3 days | HeLa | FTIR, XPS, TGA, TEM, ICP microscopy | WIST-1 assay, cell uptake, lysosome staining | The FTIR analysis demonstrated bands related to B-N and C=O in FA-BNNTs. The XPS analysis displayed strong B and N bonds in FA-BNNTs. The microscopy analysis displayed a hollow inner channel with a detailed tubular structure of nanotubes. FA-BNNTs displayed increased in cellular uptake compared to pure BNNTs. |
### Table 2. Cont.

| Authors and References | Synthesis/ Source of BNNTs | Geometrical Dimensions of BNNTs | Functionalisation/ Composition of BNNTs | Dosage and Time of Exposure | Animal Model/ Cell Line | Physiochemical Characterisation | Biocompatibility and Toxicity Assays | Outcomes |
|------------------------|-----------------------------|---------------------------------|---------------------------------------|-----------------------------|-------------------------|---------------------------------|--------------------------------------|----------|
| Nakamura et al. [59]   | --                          | --                              | Poly(ethylene glycol)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine (mPEG–DSPE) functionalised BNNTs (BNNTs–DSPE–PEG2000) | --                          | B16                     | --                              | MTT assay                            | BNNTs–DSPE–PEG2000 displayed antitumor effect on cells incubated over the time. |
| Ferreria et al. [60]   | CVD                         | Diameter: 70 nm                 | Gum Arabic (GA) functionalised BNNTs (GA-BNNTs) | 0–50 µg mL⁻¹; 1, 3, and 7 days | Rat MSCs                | TEM, FTIR, Raman spectroscopy, DLS | Cell viability, metabolic activity, cytoskeleton conformation, differentiation of stem cells into adipocytes and osteocytes at gene and phenotype | TEM images of the BNNTs displayed hallow inner channels of nanotubes, and spectroscopy results showed the presence of B and N bands. The toxicity analysis showed that BNNTs were cytocompatible with non-toxic effects on cells. |
| Li et al. [61]         | CVD                         | --                              | Europium functionalised BNNTs and doped with sodium gadolinium (BNNTs@NaGdF₄:Eu) | 0–50 µg mL⁻¹; 3 and 20 h | Human LNCap prostate cancer cells | X-ray spectrometry (XRS), TEM | Cellular uptake | Micrograph images showed nanotube with inner shells coated with EU and GD. BNNTs@NaGdF₄:Eu displayed higher cell uptake and displayed improvement of chemotherapy efficacy through magnetic fields. |
| Barachini et al. [62]  | Ball milling and annealing  | --                              | PLL functionalised BNNTs              | 0–10 µg mL⁻¹; up to 72 h | Human dental pulp stromal cells | UV–vis spectrophotometer, SEM, TEM | Cell viability, double stranded (ds-DNA) and glycosaminoglycan (GAG) contents, histological analysis | The micrographs showed that PLL-BNNTs internalised inside cytoplasm vesicles of a single DPSC. Non-cytotoxic. |
| Nitya et al. [63]      | CVD                         | --                              | BNNTs functionalised with four surfactants: Pluronic (P123), polyethyleneimine (PEI), Pluronic (P127), and ammonium oleate (A.O.) | 15.62, 31.25, 62.5, 125, 250, 500 and 1000 µg mL⁻¹; 24 h | Vero, Chang liver, MCF7 and A549 | MTT assay, DNA fragmentation assay, acridine orange staining, ethidium bromide staining | The XRD showed the hexagonal lattice of boron nitride and TEM images confirmed the presence of multwall BNNTs. BNNTs functionalised with four surfactants resulted in good cytocompatibility. |
| Ciofani et al. [64]    | CVD                         | Length: 10 μm; diameter: 1.5 nm | GA-BNNTs                             | 0–50 µg mL⁻¹; up to 72 h | SH-SY5Y and HUVECs | WST-1 assay, annexin V-FITC/propidium iodide (PI) apoptosis analysis, ROS, cytoskeleton analysis, immunofluorescence, qRT-PCR, detection of endothelial adhesion molecule expression | The morphology images showed that BNNTs were internalised in the cells. BNNTs with high purity about 20 µg mL⁻¹ displayed good biocompatibility. | SEM |
### Table 2. Cont.

| Authors and References | Synthesis/ Source of BNNTs | Geometrical Dimensions of BNNTs | Functionalisation/ Composition of BNNTs | Dosage and Time of Exposure | Animal Model/ Cell Line | Physiochemical Characterisation | Biocompatibility and Toxicity Assays | Outcomes |
|------------------------|-----------------------------|---------------------------------|-----------------------------------------|----------------------------|--------------------------|---------------------------------|-------------------------------------|----------|
| Ferreria et al. [65]   | CVD                         | –                               | BNNTs functionalised with glucosamine (GA), polyethylene glycol (PEG) 1000, and chitosan (CH) | 0 to 100 µg mL⁻¹, 48 h    | MRC-5                    | FTIR, TGA, TEM, XRD, photon correlation spectroscopy and zeta potential analysis, physical stability study, fluorescence microscope | MTT assay, ROS               | The results indicated that BNNTs were successfully obtained and functionalised, achieving a standard size and dispersity considered satisfactory for in vitro studies. BNNTs functionalised with PEG and chitosan showed significant cell damage and increase cytotoxicity at higher concentration (above 50 µg mL⁻¹). However, the results stated that no considerable changes in cell morphology or increase in ROS. |
| Danti et al. [66]      | Ball milling and annealing   | –                               | poly-L-lysine-(PLL) coated BNNTs       | 0–20 µg mL⁻¹; up to 72 h  | hOB                     | UV-vis/NIR spectrophotometer, TEM, Zeta potential distribution | MTT assay, ROS, annexin V-FITC/PI, cellular uptake, investigation of BNNTs-treated SOb cells under ultrasound irradiation, gene expression, biochemical assay, histologic analyses | The evaluation with TEM or spectroscopy confirmed that PLL-BNNTs were internalised at cytoplasm level and were noticed in membranal vesicles. The results stated PLL-BNNTs were non-cytotoxic. |
| Turco et al. [67]      | Annealing                   | –                               | Glycol (G)-chitosan (C)-coated boron nitride nanotubes(GC-BNNTs) | 0–100 µg mL⁻¹; up to 72 h | HUVECs                  | TEM, SEM, XRS and immunofluorescence microscopy | Cell viability, cell proliferation, surface enzyme immunoassay, cytoskeleton organisation and focal adhesions analysis, endothelial adhesion molecule expression | The SEM and TEM images displayed non-continuous nanotubes with no presence of regular stacking single units. TEM analysis indicated cellular internalisation after treating cells with GC-BNNTs. GC-BNNTs did not show adverse effects on cell biology or DNA damage, which resulted in non-cytotoxicity. |
| Ciofani et al. [68]    | Annealing                   | –                               | Gadolinium coated BNNTs (Gd-BNNTs)    | 0–100 µg mL⁻¹; up to 72 h | SH-SY5Y                  | ICP-MS, XRS, TEM               | WTS-I assay and DNA content quantification, cell labelling using MRI experiments | The TEM images displayed defects on the nanotubes due to functionalisation. The ICP-MS and XRS confirmed the presence of B and N elements in BNNTs. Furthermore, the EDX and ICP analyses showed Gd-BNNTs as a favourable negative contrast agent. It was stated that Gd-BNNTs were biocompatible with their ability to efficiently label and distinguish in MRI images at 7 T. |
### Table 2. Cont.

| Authors and References | Synthesis/Source of BNNTs | Geometrical Dimensions of BNNTs | Functionalisation/Composition of BNNTs | Dosage and Time of Exposure | Animal Model/Cell Line | Physiochemical Characterisation | Biocompatibility and Toxicity Assays | Outcomes |
|------------------------|---------------------------|--------------------------------|--------------------------------------|-----------------------------|------------------------|---------------------------------|-------------------------------------|----------|
| Ciofani et al. [69]    | Annealing                 | Length~500 nm                  | GC-BNNTs                             | 5 and 10 mg kg⁻¹; up to 7 days; injected into the marginal ear vein of animals | New Zealand male rabbits | DLS, SEM, TEM, X-ray spectroscopy | Blood analysis, pharmacokinetic analysis, objective symptoms such as sweating, excitement, trembling, and head nodding were analysed | The morphology images displayed bamboo-like nanotubes. The DLS confirmed good dispersion in aqueous media after modification with GC. Results stated that all doses were extremely endured by the animals, with no indication of major effects. |
| Ciofani et al. [70]    | Annealing                 | –                              | BNNTs-OH coated with 3-aminopropyl-triethoxysilane (APTES) | 0–100 µg mL⁻¹; up to 24 h | NIH/3T3 | Z-potential analysis, X-ray spectroscopy, SEM, TEM, XPS | WST-1 assay, ds-DNA quantification, cell internalisation analysis, actin staining | The atomic composition analysis confirmed the maximum percentage of B and N atoms present in BNNTs. The SEM/TEM images displayed nanotubes with small bundles of nanotubes. The functionalised BNNTs resulted in good cytocompatibility at higher concentration (100 µg mL⁻¹). |
| Soares et al. [71]     | Metallic oxide-assisted chemical vapor transport | –                              | GC-BNNTs coated with radioelement ⁹⁹mTc | 5 and 40 mg kg⁻¹; 10 and 30 min, 1 and 24 h; Injected intravenously into the tail of Swiss mice | Swiss mice | SEM, TGA, FTIR, photon correlation spectroscopy, zeta potential analysis | Radioactivity analysis, scintigraphy imaging biodistribution analysis | The morphology images confirmed the nanotubes coated with GC. The FTIR spectrum confirmed strong bands of B-N in BNNTs and –OH, C=H and C=H in GC-BNNTs. The TGA results displayed that BNNTs had less weight loss compared to GC-BNNTs. The in vivo distribution analysis indicated that major elimination of BNNTs by renal excretion and accumulation in the liver, spleen, and intestines. |
| Ciofani et al. [72]    | Annealing                 | –                              | GC-BNNTs                             | 1 mg kg⁻¹; 2, 24, and 72h; injected into the marginal ear vein of animals | New Zealand male rabbits | FIB, TEM, AFM, Size distribution, Z-potential analysis | Blood analysis to evaluate hematic parameters and live and kidney functionality | The FIB and TEM images of BNNTs showed the presence of bamboo-like shape nanotube structures with diameter ranging between 30 and 100 nm. The AFM images revealed that nanotubes edges decorated with globular structures. Z potential analysis demonstrated good stability of GC-BNNTs dispersion in aqueous medium. GC-BNNTs did not cause any organ failure or effects on blood parameters. |
| Menichetti et al. [73] | Ball milling               | –                              | PLL-BNNTs                            | 1–100 µg mL⁻¹; up to 72 h | SH-SYSY | MRI experiments, UV-vis/NIR spectrophotometry | MTT assay, metabolic activity testing, cell adhesion | The PLL-BNNTs treated at 37 showed considerable signal attenuation with increasing the concentration of BNNTs. The PLL-BNNTs compatibility in vitro at least up to 100 µg mL⁻¹. |
| Horvath et al. [74]    | –                        | –                              | –                                    | 0.05, 1, and 2 µg mL⁻¹; up to 6 days | A549, RAW 264.7, 3T3-L1, HEK 293 | SEM, TEM | Cytopathological analyses, MTT assay, FMCA assays, DNA assays | The BNNTs morphology images showed multilayered nanotubes found in the plasmalemma membrane of the cells. BNNTs induced higher toxicity in all the cell lines. |
Table 2. Cont.

| Authors and References | Synthesis/ Source of BNTNs | Geometrical Dimensions of BNTNs | Functionalisation/ Composition of BNTNs | Dosage and Time of Exposure | Animal Model/ Cell Line | Physiochemical Characterisation | Biocompatibility and Toxicity Assays | Outcomes |
|------------------------|---------------------------|---------------------------------|----------------------------------------|-----------------------------|-------------------------|---------------------------------|--------------------------------------|----------|
| Lahiri et al. [75]     | Commercial                | Length–0.4–5.8 µm; diameter 10–145 nm | BNTNs reinforced hydroxyapatite (BNTNs-HA) | 1, 3, and 5 days | Osteoblasts | SEM, TEM, XRD, nanoindentation, Vickers indent impression | Cell viability | The SEM/TEM images showed the nodular and cylindrical shaped BNTNs. The XRD results confirmed the hexanol lattice of B and N atoms. The composite with the highest BNTNs concentration displayed excellent mechanical properties. The BNTNs-HA did not induce any significant effects on cells. |
| Ciofani et al. [76]    | Annealing                 | –                               | GC-BNTNs                               | 0–100 µg mL⁻¹; up to 48 h | SH-SY5Y cells | SEM, TEM, UV–vis | MTT assay, WST-1 assay, DNA content assessment, ROS, annexin V-FITC with PI Early apoptosis detection | Cell viability | The SEM/TEM images showed a bamboo-shaped nanotube. Furthermore, the UV-vis spectrum confirmed strong absorption at 5.5 eV related to BNTNs. The cytotoxicity results with MTT-assay interfered the toxicity results and resulted in wrong toxicity data at low concentration while WST-1 showed non-toxicity above 50 µg mL⁻¹. The results stated no significant ROS or apoptosis up to 100 µg mL⁻¹. |
| Lahiri et al. [77]     | Commercial                | –                               | Poly(lactide-co-caprolactone) copolymer (PLC) reinforced with BNTNs (PLC–BNTNs) | 0, 2 and 5 wt% | Osteoblasts, murine macrophages | SEM, XRD, micro-Raman spectroscopy, tensile tests | Cell viability, gene expression, nucleic acid isolation, qRT-PCR | PLC-BNTNs incubated with cells did not increase in rate of cell death and hence resulted in non-cytotoxicity. |
| Ciofani et al. [78]    | Ball milling and annealing | –                               | PLL-BNTNs                               | Up to 72 h | C2C12 | TEM | MTT assay, live/dead assay using annexin V-FITC, metabolic activity, apoptosis detection, double stranded (ds)-DNA and protein quantification, qRT-PCR, gel electrophoresis, Western blot analysis, immunocytochemistry | The TEM images confirmed the stable dispersion with a small amount of aggregates nanotubes in dispersion agents. PLL-BNTNs did not show any difference in MyOD and Cx43 gene expression. The viability results indicated excellent cell proliferation and metabolic activity up to concentration of 10 µg mL⁻¹. |
### Table 2. Cont.

| Authors and References | Synthesis/ Source of BNNTs | Geometrical Dimensions of BNNTs | Functionalisation/ Composition of BNNTs | Dosage and Time of Exposure | Animal Model/ Cell Line | Physiochemical Characterisation | Biocompatibility and Toxicity Assays | Outcomes |
|------------------------|-----------------------------|-------------------------------|----------------------------------------|-----------------------------|-------------------------|---------------------------------|-------------------------------------|----------|
| Raffa et al. [79]      | Ball milling and annealing   | Radius–40 nm                  | PLL-BNNTs                              | Up 24 h                     | SH-SYSY                 | UV–vis/NIR spectrophotometer, focused ion beam (FIB) microscopy, electroporation analysis | MTT assay | The UV–vis/NIR quantification reported the best and repeatability absorption of PLL-BNNTs. The microscopy images showed the bundles of nanotubes. The cells exposed to BNNTs facilitated electroporation displayed excellent cell viability, metabolism, and proliferation. |
| Ciofani et al. [80]    | Ball milling and annealing method | –                             | Folic acid (FA)-PLL-BNNTs             | 10 µg mL⁻¹; 24 h            | T98G                    | FIB microscopy, UV-vis spectroscopy, Z-potential | MTT assay, cellular uptake, lysosome tracking assay, Quantum dots labelling images | The FIB images showed that the FA-PLL-BNNTs could be internalised by tumour cells. The UV-vis analysis displayed firm peaks for BNNTs and PLL-BNNTs. The Z-potential evaluation showed the strong positive Z-signals for FA-PLL-BNNTs. The functionalised BNNTs indicated ability to treat malignant cerebral tumours. |
| Chen et al. [81]       | CVD                         | –                             | –                                      | 100 mg mL⁻¹; up to 4 days   | HEK 293                 | TEM                            | Cell count and cell viability using annexin V-FITC/PI assay | The morphology images showed a bundle of nanotubes. Furthermore, the cell treated with BNNTs did not show any evidence of cell morphology changes. BNNTs treated with cells indicated no considerable effects on viability, metabolism, and cellular replication of this cell line. |
| Ciofani et al. [82,83] | Ball milling and annealing   | –                             | Polyethyleneimine (PEI)-coated BNNTs   | 10 µg mL⁻¹; up to 72 h      | SH-SYSY                 | TEM, UV–vis/NIR spectrophotometer | Trypan blue exclusion viability assay, MTT cell proliferation assay, cell uptake, cell imaging using fluorescent microscope | The morphology images showed a bundle of nanotubes. Furthermore, the cell treated with BNNTs did not show any evidence of cell morphology changes. BNNTs treated with cells indicated no considerable effects on viability, metabolism, and cellular replication of this cell line. |
3.2. The Synthesis of BNNTs

The synthesis process of BNNTs essentially depends on the conversion of B and N atoms into BN radicals [84]. Various methods to develop BNNTs depend considerably on diverse strategies, including precursors, conditions, and equipment, to obtain the high-yield BNNTs. In 1995, BNNTs were synthesised along with the analysis of their structural characteristics. The synthesis was carried out using various methods, such as laser ablation [15], chemical vapour deposition (CVD) [16], ball milling [17], substitution reaction [18], co-precipitation, and annealing [19]. All these syntheses produced BNNTs with a variety of purity levels, structures, and diameters to meet the requirements for particular physical and chemical properties. The real applications of BNNTs are still far from the market, but some laboratory-level exploration has been successfully achieved. For example, BNNTs unisation in various applications such as BNNTs reinforced polymeric composites [20], BNNTs reinforced ceramic composites [21] and hydrogen storage [22] have been carried out effectively.

3.2.1. Arc Discharge Method

Chopra et al. [3] were the first to report the experimental synthesis of BNNTs by using the arc discharge method. The procedure involved a BN rod as the precursor, which was inserted into a hollow tungsten anode electrode and arc plasma was generated between the precursor and anode to produce BNNTs. The BNNTs produced were multi-layer nanotubes with lengths of 200 nm and a diameter ranging from 1 to 3 nm [3]. The yield ratio of the obtained BNNTs was 1:1 for B:N [3]. Cumings et al. [85] reported the plasma-arc method, which can produce large-scale amounts of pure BNNTs. During the process, a grey, web-like material grew near the top of the chamber, while a thin layer of grey soot covered the side walls of the chamber [85]. Both the web-like material and the grey soot contained high amounts of BNNTs. Nevertheless, the web-like material had a slightly higher amount of BNNTs compared to the grey soot [85]. Saito et al. [86] reported BNNTs synthesised using arc discharge with the reaction between the zirconium diboride electrode in a nitrogen (N\(_2\)) atmosphere. Single-wall BNNTs, with a diameter ranging from 2 to 5 nm, were obtained with different chiral angles containing the zigzag and the armchair [86]. Recently, Yeh et al. [87] demonstrated a stable synthesis of BNNTs, with a precursor of B anode in an atmosphere of N\(_2\), using the arc discharge method. The report indicated that BNNTs produced from this method were single and multi-walled nanotubes. However, the major drawback of the arc discharge method is that it is challenging to manufacture BNNTs at commercial quantity, as the reaction zone at the arc core is limited to a modest capacity [84].

3.2.2. Ball Milling Method

Ball milling is another method utilised to synthesise BNNTs [88]. Chen et al. [89] demonstrated the synthesis of BNNTs with a boron powder ball milled under ammonia (NH\(_3\)) gas for 150 h and subsequently annealed at 1000 to 1200 °C in the N\(_2\) environment. The report stated that the long hours of milling through the nitration process resulted in high-yield BNNTs. Gerald et al. [90] described the BNNTs produced from precursors (tungsten carbide) in a ball mill. The characterisations of the study stated that thick-walled BNNTs were produced in milling conditions under an ammonia atmosphere. Similarly, other researchers produced BNNTs using various catalysts, mainly iron(III) chloride (FeCl\(_3\)) [91], iron (Fe) [6], ferric nitrate (Fe(NO\(_3\))\(_3\)) [92], iron(II, III) oxide (Fe\(_3\)O\(_4\)) [93], B [94], and silicon carbide (SiC\(_7\)/SiC) [95]. The synthesised BNNTs were mostly in bamboo-like nanotube shapes with a diameter ranging from 50 to 200 nm with a length of 1.0 mm.

3.2.3. Laser Ablation

The laser ablation method is used to synthesise BNNTs at higher temperatures. Goldberg et al. [96] demonstrated the synthesis of BNNTs through laser heating of precursor cubic-BN and hexagonal-BN in a diamond anvil in the N\(_2\) atmosphere. The obtained BNNTs were 3–15 nm in diameter. In another study, Yu et al. [97] reported the production
of BNNTs using the evaporation of BN, along with cobalt and nickel at 1200 °C in the presence of a laser beam. The findings stated that the BNNTs had a diameter ranging from 1.5 to 8 nm. Additionally, it was further stated that the tips of nanotubes were either flat cap or semi-circular [97]. Smith et al. [98] demonstrated the synthesis of the long single- and multi-walled BNNTs through the pressurised vapour condition. BNNTs of 3 cm in length were obtained. More recently, Kim et al. [99] reported dual growth modes of BNNTs using a high-temperature pressure laser ablation. It was observed that BNNTs with both closed- and open-end nanotubes were obtained [99].

3.2.4. Thermal Plasma

Thermal plasma is another technique used to produce BNNTs. This method is similar to the laser ablation technique but capable of producing a large volume of BNNTs. Kim et al. [100] demonstrated producing BNNTs of small diameter (~5 nm) using hexagonal-BN by the thermal plasma technique. BNNTs with high crystallinity, purity, and yield were produced without needing a higher amount of catalyst [100]. Similarly, Fatollahizadeh et al. [101] described a low-wall number BNNTs synthesis method using the thermal plasma method. The result showed that catalyst-free BNNTs with a production rate of 35 g·h⁻¹ was obtained [101]. Compared with the laser ablation method, the production rate is 300 times higher than the thermal plasma process [101]. Recently, Kim et al. [102] reported that BNNTs were synthesised using direct current thermal plasma. The report stated that the high-yield BNNTs were produced at a production rate of 12.6 g·h⁻¹. BNNTs with a diameter of 7 nm were obtained with low input power and gas. Hence, thermal plasma provides an efficient way to mass-produce BNNTs with high quality [102–104].

3.2.5. Chemical Vapour Deposition (CVD) and Thermal Annealing

The CVD method has been playing a promising role in synthesising BNNTs. In this process, the yield and structure of the BNNTs are mainly based on the precursor, catalyst, temperature, gas, and equipment. Experimentally, BNNTs grown in the CVD method are commonly through horizontal or vertical furnaces at high temperatures. Furthermore, the furnace with dual temperatures was also considered in the synthesis of BNNTs using CVD. Lee et al. [105] applied the CVD method with a precursor loaded in a quartz tube and placed the tube in a horizontal furnace. The design was used to grow the BNNTs through flowing NH₃ and react with the precursor to obtain high BNNTs. Recently, Koken et al. [10] reported the synthesis of BNNTs at a temperature of 1050 °C with the precursor (colemanite) and catalyst (Fe₂O₃) through CVD. The produced BNNTs were multi-walled with a diameter of 62 to 82 nm. The CVD technique is studied with various precursors, catalysts, and temperatures to produce BNNTs [106].

In addition to the methods mentioned above, there are other synthesis techniques to produce BNNTs; for example, the co-precipitation and annealing method, where B powder, Fe₂O₃, and urea were mixed to obtain a precursor and annealed at 1200 °C for 5 h [8]. The grown BNNTs had a diameter ranging from 10 to 80 nm with the shape of bamboo and quasi-cylindrical [8]. Another method was heating the B powder, Fe₂O₃, and ammonium chloride in the autoclave at 600 °C for 12 h [106,107]. The diameter of obtained BNNTs was 100 nm. To better understand these techniques, they are summarised in Table 3.

| Methods                  | Temperature (°C) | References                           |
|--------------------------|------------------|--------------------------------------|
| Arc-discharge            | >3426.85         | [3,85,87,108–110]                    |
| Laser ablation           | 1200–5000        | [96,98,111–113]                      |
| Ball mill/annealing      | 1000–1300        | [6,88–92,114–121]                    |
| Template synthesis       | 500–1580         | [122–129]                            |
| Thermal plasma           | >526.85          | [84,100–102,130]                     |
| CVD                      | 1100–1700        | [131–143]                            |
| Autoclave                | 450–600          | [107,144,145]                        |
Overall, the thermal plasma method is currently applicable in the commercial production of BNNTs. The cost of 100 mg of BNNTs is within USD 100 [18]. However, ongoing research and development will continue to obtain more efficient methods to produce higher purity and yield BNNTs to stimulate the availability of the material.

3.3. BNNTs Functionalisation, Modification, and Types of Composites

Although BNNTs possess excellent characteristics and are recognised as structural analogues of CNTs, the hydrophobic nature of BNNTs limited their utilisation in biomedical applications. One of the major drawbacks of using pristine BNNTs in cell culture is the tendency to form agglomeration [81], which can affect both cell proliferation and biocompatibility evaluation [65,81]. Thus, the initial step to employ BNNTs in biological systems is to obtain the homogenous dispersion of BNNTs in aqueous media or in other physiological media [146,147]. To overcome this limitation, the functionalisation of the surface of BNNTs with various approaches such as covalent [148], noncovalent [149], defect reaction, and inner-space filling [150,151] were employed to give nanotubes a good dispersibility in water and biological mediums (Figure 3a). Additionally, BNNTs were functionalised with lipids [23], antibodies [152], peptides [153], specific molecules, or quantum dots [146] to uncover the full possibilities of using BNNTs in biomedical applications. The illustration of BNNTs functionalisation is shown in Figure 3.

Experiments were conducted through various consecutive steps of thermal stirring and sonication with various agents such as glycol-chitosan (GC) [76]; poly-L-lysine (PLL) [78]; methoxy–poly(ethylene glycol)–1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N conjugate (mPEG-DSPE) [23]; polyethylenimine (PEI) [82]; 3-aminopropyltriethoxysilane (APTES) [70]; doxorubicin (DOX) and deoxyribonucleic acid (DNA), to obtain stable dispersion of BNNTs in cell-culture mediums.

3.4. Cell Sources

The most dominant cell types used in the included articles were human embryonic kidney cells (HEK293, HEK293T) [24,25,74,81,154], human neuroblastoma cells (SH-SY5Y) [30,64,68,73,76,79,82,155], mouse embryonic fibroblasts (NIH/3T3) [70], human dermal fibroblasts (HDF) [31,36,48,51,55], lung fibroblasts (MRC-5) [65,156], dental pulp...
fibroblasts [34,41,62], lung epithelium cells (A549) [37,55,74], macrophage cells (RAW 264.7) [49,74], human liver epithelium (HeP G2) [27,28,37], human peripheral blood (NB4) [37], glioblastoma cells (malignant U87 [30,37,156], T98 [80,156]), mammary gland adenocarcinoma cells (MCF-7) [156], N9 murine microglia cells [50], osteoblasts [54,66,75,77], osteoblast precursor cell line derived from mouse musculus calvaria (M3CT3) [47], THP-1 [45], NLRP3-deficient human monocytes [45], human osteosarcoma cell line (SAOS-2) [31,39], murine macrophages [77], Henrietta Lacks (HeLa) [35,42,43,58], CD34+ cells [35], V79 cells [35], bronchoalveolar lavage cells (BAL) [29], B16 melanoma [59], human LNcap prostate cancer cells [61], human endothelial cells (HUVECs) [64,67], human hepatocytes (L02) [27], C2C12 mouse myoblasts [36,56,75,155], human peripheral blood (PBMC) [38], bone-marrow mesenchymal stem cells (MSCs) obtained from bilateral femora from Fischer 344/N syngeneic rats [52], MSCs [60], human prostate adenocarcinoma cells (DU145) [44], MDA-MB-231-luc2 cells [46], and human keratinocytes (HaCaT) [33] to assess the toxicity and biocompatibility of the BNNTs.

3.5. Methods Evaluating In Vitro Biocompatibility of BNNTs

3.5.1. Cell Viability Assays

In the selected articles various methods have been used to analyse the effects of the BNNTs-incubated cells on cell viability and cytotoxicity assays (Figure 4a). The most commonly used evaluations were 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) [31,35,76,78,82,156], 2-(4-iiodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium (WST-1) [68], alamarBlue™ [30], Trypan Blue assay [78,82], tetrazolium-8-[2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium] monosodium salt (CCK-8) [27], lactate dehydrogenase (LDH), and amido black assay [67]. These assays are calorimetric methods to evaluate cell viability, proliferation, and cytotoxicity. For instance, MTT assays are dissolved in a solubilisation solution that results in a coloured solution with absorbance at 500–600 nm, using a spectrophotometer. Subsequently, WST-1 assay is a water-soluble assay with greater stability and sensitivity, providing rapid measurements. Another method is LDH assay, which is used to evaluate the level of plasma-membrane damage in cell population. Another very simple method is Trypan Blue assay. Trypan Blue highlights the dead cells that are easily observed under bright-field microscopy [24,25,82].

Cytotoxicity of BNNTs can be detected by staining the live and dead cells. The staining reagents penetrate the living cells and transform the membrane into fluorescent dye colours such as blue, green, and red, which can be detected with flow cytometry and fluorescence microscopy [146,157]. To identify the BNNTs cytotoxicity, the studies used calcein AM [31,68], ethidium homodimer III (Ethd-III) [68], annexin V-Fluorescein (FITC)/PI [27,42,49,64,66,76] assay, actin staining [29] and 4′,6-diamidino-2-phenylindole (DAPI) staining and trizima solution [33].

3.5.2. Total Reactive Oxygen Species

Generally, BNNTs (foreign matter) incubated with cells tend to increase reactive oxygen species (ROS) [40,45,64–66,76]. The inclined ROS levels cause cellular stress that can be observed using oxidation-sensitive fluorescent dyes like 5-(and-6)-carboxy-2′,7′-dichlorodihydrofluorescein diacetate (carboxy-H2DCFDA) [157]. The evaluation is carried out by flow cytometry in the FITC channel and fluorescence microscopy. The oxidative stress may increase due to sudden changes in environmental conditions or during infection, which causes damage to cellular proteins, lipids, and DNA that has been associated with inflammation, cancer, and other physiological conditions.

3.5.3. Genotoxicity Evaluation

Genotoxicity testing is performed to detect and identify hazards, and to determine the mutation of germ cells and cancer development (Figure 4b) [46]. The genotoxicity of BNNTs can be assessed using the comet assay [35,40,57]. The comet assay can be used with in vivo
and in vitro evaluation of genotoxicity. The single-cell gel electrophoresis assay detects low levels of DNA damage in a small number of cells. Measurements of genotoxicity are carried out using Comet IV software or manual counting.

3.6. BNNTs Biocompatibility In Vitro

BNNTs in biomedical applications have been studied in in vitro assessments using various cell lines to understand the toxicity levels and biocompatibility. Ciofani et al. [82] (in 2008) first reported the toxicity of BNNTs, using SH-SY5Y cells. The BNNTs were functionalised with polyethyleneimine (PEI) and incubated in the cell line for up to 72 h to evaluate the toxicity [82]. The viability tests were carried out using Trypan Blue and MTT assay [82]. The results stated that PEI-coated BNNTs were non-cytotoxic and displayed no
negative effects on cell functions [82]. Furthermore, it was mentioned that due to the PEI on the surface of the BNNTs, the cell-uptake mechanisms were not impacted. The outcomes of the study stated that BNNTs did not show any significant toxicity levels, up to 5 µg·mL\(^{-1}\) for up to 72 h [82]. Similarly, Raffa et al. [79] demonstrated the toxicity of BNNTs using the same cell lines with different functionalisation material. The study as carried out on PLL-coated BNNTs (PLL-BNNTs). Furthermore, the BNNTs were tested as a nanotool to facilitate cell electropermeabilisation (EP) with extremely low electric fields varying from 40–50 V/cm [79]. The results demonstrated that the presence of BNNTs (facilitated with EP) displayed high cell viability, metabolism, and proliferation. In addition, BNNTs mediated with EP aided in increasing cell permeabilisation with low voltage to allow chemicals or DNA to be introduced into cells for drug delivery and therapeutic treatments [79]. Using the same human neuroblastoma cells, Ciofani et al. [76] explained the cytocompatibility and stability that was attained through BNNTs wrapped with glycol-chitosan (GC-BNNTs). The various concentrations of GC-BNNTs (0, 5, 10, 20, 50 and 100 µg·mL\(^{-1}\)) were incubated in cells for 48 h and assessed with both MTT and WST-1 assay [76]. The results stated that the BNNTs at higher concentrations showed optimal cytocompatibility with no adverse effects on viability, toxicity, early apoptosis, and ROS. Moreover (and interestingly), the results stated that the MTT assay showed false cytocompatibility findings due to the BNNTs interactions with tetrazolium salts that hindered the results, which showed a viability decrement of 10 µg·mL\(^{-1}\). However, a water-soluble assay, namely WST-1, indicated that intrusion did affect the enzymatic reaction, with no decrease in viability at 10 µg·mL\(^{-1}\) [76]. Furthermore, the early apoptosis detection and ROS detection performed after 48 h showed no evidence of significant negative effects with cells incubated with different concentrations of BNNTs-GC [76]. Similarly, other studies carried out using the same cell line showed significant cytocompatibility in vitro, up to 100 µg·mL\(^{-1}\) [68,73] (See Table 2).

3.6.1. Human Embryonic Kidney Cells

Chen et al. [81] showed the biocompatibility of BNNTs with HEK cells. The BNNTs were synthesised using a chemical vapour technique (CVD) with a geometry of 20–30 nm diameter and lengths ranging up to 10 mm [81]. The BNNTs were incubated in HEK 293 cells without any functionalisation, up to 100 mg·mL\(^{-1}\) [81]. Additionally, the toxicity of BNNTs was compared with CNTs of similar length and diameter. The results indicated that BNNTs showed similar cell growth in control (cells cultured in a medium without nanotubes) [81]. In contrast, CNTs showed a significant decrease in cell growth after 4 days [81]. Furthermore, the apoptosis and necrosis analysis with annexin V-FTIC/propidium staining on cells treated with BNNTs and glycodendrimer coated BNNTs observed that BNNTs directly bind to cell surfaces [81]. This easy method demonstrated that coated BNNTs and uncoated BNNTs revealed comparable dendrimer-bearing galactose deposits that were adept at cooperating with proteins and cells [81].

3.6.2. T98g and Fibroblast Cells

In another study, the cytocompatibility of BNNTs with yields of 80 and 97% purity was functionalised with PLL (PLL-BNNTs) and was evaluated using T98G cells and human gingival fibroblasts [80]. Furthermore, the functionalised BNNTs were bound with folic acid (FA) to obtain folate conjugated PLL-BNNTs (FA-PLL-BNNTs) [80]. Both the PLL-BNNTs and FA-PLL-BNNTs were covalently identified with carboxyl-derivatised quantum dots for cellular-tracking studies [80]. After 24 h of treatment at 10 µg·mL\(^{-1}\) concentrations of both PLL-BNNTs and FA-PLL-BNNTs, the contents displayed complete cytocompatibility of PLL-BNNTs with both cell lines [80]. Furthermore, cell viability assayed using Trypan Blue displayed >95% viability in each case [80]. The MTT assay displayed excellent metabolic activity (80%) for both cells, with no significant difference to the control [80].
3.6.3. Human Osteoblasts Cells

Danti et al. [66] investigated the toxicity of PLL-BNNTs using a different cell line (primary human osteoblasts (HOBs)) and the effects of BNNTs with an ultrasound stimulatory method on cell function and maturation was studied [66]. The MTT viability assay displayed excellent metabolic activity of the treated cells with PLL-BNNTs after 72 h [66]. The early apoptotic and necrotic phenomenal showed no substantial variation in both control and PLL-BNNTs-treated cells after 24 and 72 h [66]. Furthermore, the osteoblast-cell internalising BNNTs that were irradiated with low-frequency ultrasound showed improved in protein concentration with respect to the controls [66]. Lahari et al. [77] addressed the cytotoxicity of the BNNTs-reinforced polylactide-polycaprolactone copolymer (PLC) composites using both HOBs and macrophage cells. The cytotoxicity evaluation was carried out using an LDH assay and showed no adverse effects of the BNNTs-reinforced polymer in both cells [77]. Furthermore, BNNTs-reinforced PLC increased the cell viability rate on composite films. More interestingly, it was observed that fourfold and sevenfold increases occurred in levels of expression of transcription factor Runx2 in composite films [77]. The same group studied the biocompatibility of hybrid composite produced by BNNTs mixed with hydroxyapatite (BNNTs-HA) using HOBs [75]. The results stated an accelerated osteoblast-cell viability and proliferation within the presence of BNNTs [75].

In another study, Fernandez-Yague et al. [54] validated BNNTs functionalised with polydopamine (PD) cytocompatibility using HOBs at concentrations of 1, 10, and 30 µg·mL⁻¹. The quantification of cell viability with PD-coated BNNTs-treated cells showed good metabolic activity with a 90% proliferation rate, while uncoated BNNTs showed reduced metabolic activity and proliferation rates compared to control conditions [54]. Moreover, the study stated that PD-coated BNNTs localised to the HOB plasma membrane can be deposited on the cell surface, acting as a protective layer and preventing endocytosis of isolated nanotubes [54]. Furthermore, the PD-coated BNNTs were internalised by cells as individual entities [54]. Another interesting investigation reported by Farshid et al. [47] was on BNNTs-reinforced poly(propylene fumarate) (PPF-BNNTS) in vitro cytotoxicity, using MC3T3 pre-osteoblasts. The cell viability was determined by the resazurin-based Presto Blue® assay. It was reported that 1 µg·mL⁻¹ PPF-BNNTs showed 100% cell viability while 100 µg·mL⁻¹ showed 99 ± 13% [47]. The results suggested good cell viability, attachment and spreading of MC3T3 cells on all experimental groups [47].

3.6.4. Fibroblast Cells

Ciofani et al. [70] reported on in vitro biocompatibility and cellular uptake of BNNTs functionalised with amino salts, using fibroblast (NIH/3T3) cells. An aminosilane named APTES was presented as a surface functionalisation agent for the BNNTs. This opened up various interesting perspectives for BNNTs modification using biomolecules [70]. The obtained BNNTs-coated APTES were incubated with NIH/3T3 cells for up to 72 h to study the viability rate of cells [70]. The WST-1 assay showed (after 24 h) excellent metabolic activity and viability of cells treated with 100 µg·mL⁻¹ functionalised BNNTs [70]. However, after 72 h a decrement in viability rate was observed—about 16% at both 50 and 100 µg·mL⁻¹ concentration of BNNTs [70]. DNA concentration analysis showed similar results as the WST-1 assay with no significant effects after 24 h at higher concentrations. While there were decreases up to 20% at 50 µg·mL⁻¹ and 100 µg·mL⁻¹ BNNTs concentration after 72 h [70]. The confocal microscopy images of actin-stained cells treated with f-BNNTs displayed no evidence of f-BNNTs in cell nuclei [70]. Consequently, f-BNNTs demonstrated optimal cytocompatibility at higher concentrations, with stable dispersion [70].

Emanet et al. [48] prepared the hydroxylated BNNTs (BNNT-OH)-chitosan scaffold and tested their mechanical strength, swelling behaviour and biodegradability. The results showed that the inclusion of BNNTs-OH into the chitosan scaffold increased the mechanical strength and pore size at optimal for high cellular proliferation and adhesion [48]. The chitosan-BNNT-OH scaffold was also found to be non-toxic to human dermal fibroblast (HDF) cells due to their slow degradation rate. The results were confirmed with DAPI-
stained cells proliferated on a chitosan-BNNT-OH scaffold better than the cells on the chitosan-only scaffold [48].

In another study, Émanet et al. [55] reported functionalisation of the BNNTs by hydroxylation (h-BNNTs) and carbohydrate modification to increase the cellular uptake and dispersibility of the nanotubes. Glucose, lactose, and starch-modified BNNTs (m-BNNTs); BNNTs and h-BNNTs (5–200 µg mL\(^{-1}\)) were incubated (1–3 days) with two cell lines (HDF and A549) to evaluate the cytotoxicity and the genotoxicity [55]. The A549-cell viability declined to 40% and 60%, while the HDF-cell viability reduced to 90% during the second and third days of the incubation with BNNTs and h-BNNTs [55]. In addition, m-BNNTs showed no adverse effects on the viability of HDFs and A549 cells [55]. Meanwhile, the ROS production significantly increased in BNNTs and h-BNNTs-exposed cells up to 70 and 110%, in both cases [55]. In contrast, the ROS production was not significant (20 and 30%) in m-BNNT-exposed cells, with respect to the control cultures [55]. With the comet assay, BNNTs and h-BNNTs-treated cell tail-lengths were approximately 38%, while the m-BNNT-exposed cell tail-lengths were 20% and 30% if compared to the positive control cells, which were exposed to hydrogen peroxide [55]. Hence, the outcomes showed that the increase in ROS levels in the cells was due to DNA damage [55]. Furthermore, the analysis indicated that BNNTs and h-BNNTs were cytotoxic, but m-BNNTs were biocompatible for various biomedical applications without significant damage to healthy cells [55].

Sen et al. [51] studied the biocompatibility of BNNTs-reinforced gelatine and glucose scaffolds produced using an electrospinning technique. The biocompatibility tests were carried out using HDF cells incubated with BNNTs-gelatine scaffolds after exposure for up to 7 days [31]. The results stated that the scaffolds did not substantially impact the cell viability rate (Figure 5) [31]. In other studies, Diez-Pascual et al. [53] reported polyethylene glycol (PEG)-grafted BNNTs-reinforced poly (propylene fumarate) (PPF) nanocomposite biomaterials for tissue-engineering applications. The cytotoxicity of PPF-PEG-g-BNNT nanocomposites was assessed by culturing with HDF [53]. The viability results of various concentrations of PPF-PEG-g-BNNT (0.0–4.0 wt%) showed negligible toxicity towards HDF cell lines after 24 h [53]. Thus, the covalent grafting of BNNTs with PEG reduced the cytotoxicity towards the cells and likely aid in good dispersion of BNNTs in aqueous media [53].

Ferreira et al. [65] investigated the cytocompatibility of BNNTs functionalised with organic hydrophilic agents composed of glucosamine (GA), polyethylene glycol (PEG) 1000 and chitosan (CH). In vitro studies of f-BNNTs were conducted using lung fibroblast MCR-5 cells [65]. The functionalised BNNTs (0.1–50.0 µg mL\(^{-1}\)) treated with cells showed an approximately 90% viability rate after 48 h [65]. At higher concentrations of 100 and 200 µg mL\(^{-1}\) the viability was approximately 50% and 25% in samples of BNNTs-CH and BNNTs-PEG [65], while BNNTs-GA maintained excellent viability (>90%) up to 100 µg mL\(^{-1}\) after 48 h. Furthermore, with BNNTs-GA, the results stated that no significant chromosomal damage, DNA damage, or ROS increase was observed, up to a concentration of 50 µg mL\(^{-1}\) [65]. However, concentrations above 50 µg mL\(^{-1}\) in BNNTs-CH and BNNTs-PEG resulted in significant cell damage and increased cytotoxic activity [65].

Degrazia et al. [41] reported the cytotoxicity of a methacrylate-based adhesive containing BNNTs using fibroblast cells in derived dental pulp. The results stated that cell viability of fibroblasts after 72 h was enhanced up to 10% when 0.05 wt% BNNTs were incorporated into methacrylate-based adhesive [41]. Furthermore, it was stated that the cytocompatibility depended on the purity, concentration, and functionalisation of BNNTs [41]. Similar studies have been conducted by Bohns et al. [34] and Barachini et al. [62] to analyse the BNNTs cytotoxicity with fibroblast cells derived from dental pulp. It was reported that BNNTs incubated with cells do not have any significant effect on the viability of cells.
3.6.5. HeLa Cells

Ferreira et al. [43] investigated the cytocompatibility of BNNTs using HeLa cells. Concentrations of 10, 50, 100, and 200 µg·mL⁻¹ of BNNTs were incubated with cells for 2 days and viability was assessed using WTS-1 assay [43]. The results showed that the viability rate was more than 80% for all concentrations [43]. Furthermore, a cell-irradiation assay was carried out to promote cell-death signalling in tumour cells, which showed minor toxicity where BNNTs were internalised [43]. Overall, the biological assays showed that the BNNTs had a suitable cell viability and that irradiation with an appropriate flux
of thermal neutrons did not cause significant damage in the cells studied [43]. In another study, BNNTs functionalised with folic acid (FA) were incubated with HeLa cells to evaluate the cytocompatibility [58]. The in vitro assays tests indicated that no adverse effects were found on HeLa cells cultured with FA-BNNTs and BNNTs in a concentration range of 0–50 µg·mL$^{-1}$ [58]. Furthermore, the internalisation assessment revealed that BNNTs were located outside the cells, while FA-BNNTs were highly internalised by the cells, indicating an active role in the cell-uptake process (Figure 6) [58].

![Figure 6](image-url) 

**Figure 6.** (a) Confocal images of HeLa cells treatment with BNNTs and FA-BNNTs; (b) FA-BNNTs internalisation by HeLa cells; (c) lysosome staining (in green) for FA-BNNT (in pink) co-localisation evaluation. Reproduced with permission from Ref. [58]. Copyright 2015, Elsevier.

### 3.6.6. Human Umbilical Vein Endothelial Cells

Del Turco et al. [67] also studied the effects of GC-BNNTs (0–100 µg·mL$^{-1}$) incubated with HUVECs for 48 and 72 h. It was reported that no adverse effects were identified in cell viability, the cytoskeleton, or DNA damage. Another interesting study used gum Arabic (GA) as a non-covalent functionalisation agent to obtain dispersion and stability of suitable length and aspect ratio of the nanotubes [64]. The obtained gum-Arabic-coated BNNTs were cultured in both HUVECs and SH-SY5Y cells, with concentrations of 0–100 µg·mL$^{-1}$ [64]. The viability tests conducted using WST-1 assay for SH-SY5Y and Amido Black assay for HUVEC cells demonstrated that the BNNTs viability rate was not statistically different from the control cultures, up to 20 µg·mL$^{-1}$ after 72 h [64]. However, there was a significant decrease in the rate of viability in higher concentrations, after 72 h [64]. The micrograph images showed that cells failed to reach confluence after 72 h in higher concentrations over 20 µg·mL$^{-1}$ [64]. Additionally, the results stated that no adverse toxic effects were displayed (up to 20 µg·mL$^{-1}$) on both cell types in terms of ROS production and apoptosis induction [64]. It was highlighted that BNNTs were suitable for in vitro biomedical applications (up to 20 µg·mL$^{-1}$) with a suitable length and aspect ratio of the nanotubes [64].
3.6.7. Human Osteosarcoma Cells

Marcos da Silva et al. [31] conducted a study using an in vitro assay on BNNTs incorporated with samarium and gadolinium (GdBO$_3$-BNNTs) with a human osteosarcoma cell line (SAOS-2) and HDF cells. The samples in a concentration of 10 µg·mL$^{-1}$ showed high biocompatibility both with fibroblasts (92% cell viability) and with SAOS-2 cells (70% cell viability) [31]. A concentration of 50 µg·mL$^{-1}$ indicated low biocompatibility with fibroblasts (50% cell viability) but high biocompatibility with SAOS-2 cells (80% cell viability) [31]. The results suggested that biocompatibility relied on low concentrations and the osteosarcoma cells were more resistant to this material than normal cells [31]. The results showed that the GdBO$_3$-BNNTs can be used in scintigraphy radiotracers or as MRI contrast medium, being able to promote the treatment of many types of tumors simultaneously with their diagnosis [31]. Genchi et al. [39] investigated piezoelectric films of BNNTs-reinforced poly(vinylidenedifluoride-trifluoroethylene) (PVDF-TrFE-BNNTs) that were prepared by cast annealing and used SAOS-2 cells to evaluate the cytocompatibility. The percentage of Alizarin Red-stained areas of piezoelectric PVDF-TrFE-BNNTs films was higher with absence or presence of ultrasound. Moreover, the markers were significantly increased in cells cultured on PVDF-TrFE-BNNTs films [39].

3.6.8. Mesenchymal Stem Cells

In another study, Li et al. [52] described the interaction between BNNTs and mesenchymal stem cells (MSCs). The results stated that BNNTs displayed an increase in protein absorption and enhanced the cell proliferation of MSCs that improved the secretion of total protein by MSCs [52]. In addition, BNNTs increased the alkaline phosphate activity as an early marker of osteoblasts and osteocalcin as a late marker of osteogenic differentiation [52]. Overall, it was reported that BNNTs were able to enhance the osteogenesis of MSCs, which showed potential in bone regeneration in orthopaedic applications [52]. Ferreira et al. [60] incubated GA-BNNTs in MSCs to investigate the cytocompatibility. The cell viability and proliferation were not affected, up to 20 µg·mL$^{-1}$ of GA-BNNTs [60]. The cytoskeleton study revealed a significant reorganisation of the forms based on f-actin staining, because of uptake of the GA-BNNTs [60]. Additionally, it was indicated that BNNTs enhanced the differentiation of MSCs into adipocytes (but not into osteocytes) and led to an increase in mRNA level for adipocyte differentiation [60].

3.6.9. MDA-MB-231-luc2 Cells

Sen et al. [46] demonstrated that BNNTs could be functionalised with oligonucleotides (oligo-BNNTs) and chemically hybridised to morpholinos (morpholino/oligo-BNNTs). The hybridised composite used delivery of morpholinos into MDA-MB-231-luc2 cells [46]. The gene-slicing assessment stated that luciferase activity decreased when MDA-MB-231-luc2 cells were treated with morpholino/oligo-BNNTs, which showed gene-slicing efficiency [46]. The WST-1 assay displayed that the scrambled morpholino/oligo-BNNTs, scrambled lipofectamine, morpholino/oligo-BNNTs, and morpholino-lipofectamine did not significantly affect cell viability (88 ± 4% for all) [46].

3.6.10. Glioblastoma Cells

Niskanen et al. [50] evaluated the response of cells such as N9 microglia and U251N glioblastoma to BNNTs coated with glycine and loaded with model drug, curcumin, and fluorescent probes. The length of the BNNTs was approximately 2 µm with the ends opened up due to the sonication process [50]. The cell viability tests uncovered that microglia cell death occurred when exposed to a BNNT concentration over 10 µg mL$^{-1}$ [50]. However, U251N cells remained viable when they were exposed to the higher concentration of BNNTs, under the same conditions [50]. In contrast, the viability of U251N cells was reduced after 24 h of exposure to the higher concentration. Whereas curcumin-g-BNNTs incubated with microglia cells was decreased in the viability at a concentration higher than 50 µg·mL$^{-1}$, the U251N cell loss was 25.3 ± 6.3% at 50 µg·mL$^{-1}$ [50]. The mitochondrial metabolic activity
of cells indicated that drugs such as curcumin can be effectively incorporated into BNNTs, internalised by tumour cells, and can release therapeutic effects [50]. The curcumin-loaded BNNTs reduced the inflammation from microglia cells stimulated with LPS. However, curcumin-g-BNNTs showed reduced metabolic impairment caused by BNNTs devoid of curcumin [50].

3.6.11. Vero, Chang Liver, MCF7, and A549 Cells

Nitya et al. [63] used BNNTs functionalised with four different surfactants such as Pluronic-P123, PEI, Pluronic-F127, and ammonium oleate (A.O.) to investigate their antibacterial properties and conduct cytotoxic studies. The pristine BNNTs and surfactant-coated BNNTs were evaluated to interpret their antibacterial activity and cytotoxicity levels in various cells such as Vero, Chang liver, MCF7, and A549 cells [63]. The toxicity levels were analysed using an MTT assay. The results stated that the F127-coated BNNTs and pristine BNNTs showed good viability rates in all cell lines, up to 250 µg·mL⁻¹ [63]. P123 and A.O.-coated BNNTs showed no adverse effects, up to 125 µg·mL⁻¹ [63]. However, PEI functionalised BNNTs showed significant toxicity levels on Vero and Chang liver cells at lower concentrations [63]. In addition, DNA fragmentation of F127-coated BNNTs indicated the apoptotic pathway of cell death in cancer cells [63].

3.6.12. Other Types of Cells

Rocca et al. [49] investigated pectin-coated BNNTs (P-BNNTs) incubated with RAW-264.7 macrophages to evaluate in vitro cyto- and immune-compatibility. The WST-1 assay results demonstrated that cell metabolism was not altered by P-BNNTs treatment at all the considered concentrations with respect to the control cultures [49]. The proliferation rate was assessed using Quant-iT™ PicoGreen® ds-DNA assay, which showed no differences in terms of DNA concentration in the treated samples, compared to the control [49]. Flow-cytometry measurements of necrotic/apoptotic phenomena finally exhibited that an acute treatment with P-BNNTs, up to 50 µg·mL⁻¹, did not cause a statistically significant growth of necrotic, early apoptotic, or late apoptotic cells in comparison to a control culture [49]. Furthermore, P-BNNTs did not stimulate inflammation responses, both at protein and gene levels [49]. Poudel et al. [38] analysed the cellular response to piezoelectric materials composed of PVDF-TrFE-BNNTs and evaluated cytocompatibility using human-tendon-derived cells. The cell-proliferation assays confirmed that cells cultured on PVDF-TrFE/BNT nanocomposites demonstrated enhanced proliferation for up to 10 days in culture relative to pure PVDF-TrFE films [38].

Pasquale et al. [30] investigated the BNNTs doped with doxorubicin (Dox) and coated with cell membranes (CM) derived from glioblastoma multiforme (GBM-a brain-cancer cell type) cells (Dox-CM-BNNTs) that are able to kill GBM cells in vitro while leaving healthy brain cells unaffected. The anti-cancer properties of Dox-CM-BNNTs at various concentrations such as 25, 50, 100, and 200 µg·mL⁻¹ were examined on U87 MG glioblastoma cells and related to the cytotoxicity of CM-BNNTs and mPEG-DSPE-BNNTs [30]. The results showed that cell viability decreased in both Dox-CM-BNNTs and free Dox after 24 and 72 h in all concentrations [30]. However, the CM-BNNTs and mPEG-DSPE-BNNTs did not show any significant effects on the cells [30]. The reports highlighted that 100 µg·mL⁻¹ Dox-CM-BNNTs displayed a significant cell-death rate and resulted in anti-cancer effects [30].

Li et al. [61] examined the utility of BNNTs@europium-doped sodium gadolinium fluoride (BNNTs@NaGdF₄:Eu) for fluorescence imaging and magnetic targeting, especially for cancer therapy (Figure 7). BNNTs@NaGdF₄:Eu was incubated with human LNcaP prostate-cancer cells to evaluate the influence of a permanent magnetic field and in vitro cell uptake [61]. The fluorescence intensity results indicated that for mediums containing 20 µg·mL⁻¹ of BNNTs@NaGdF₄:Eu, a significant cell uptake of 404 ± 30 was observed in the presence of a magnetic field and in the absence of a magnetic field it was 315 ± 18, while for pure cells in the presence of a magnetic field it was 230 ± 3 [61]. Furthermore, the
cancer-cell viability in the absence and presence of a magnetic field was measured through 30% of Dox loading BNNTs@NaGdF₄:Eu [61]. The viability rate of human LNcaP prostate cancer decreased after exposure to dox-BNNTs@NaGdF₄:Eu in the presence of a magnetic field [61]. In contrast, in the absence of a magnetic field, the value was higher than it was in the presence of a magnetic field. Moreover, the multifunctional BNNTs composites showed potential in enhancement of chemotherapy with efficient use of magnetic fields [61].

![Image](a) Fluorescence image of Dox loading BNNTs@NaGdF₄:Eu; (b) LNcaP prostate cancer cells fluorescence image; (c) Overlapped fluorescence image in red colour emissions of composites uptake by cancer cells; (d) Photoluminescence emission spectrum loading BNNTs@NaGdF₄:Eu; (e) Function of magnetisation at room temperature for BNNTs@NaGdF₄:Eu composites. Reproduced with permission from Ref. [61]. Copyrights 2014, Royal Society of Chemistry.

Ferreira et al. [32] validated the tumour-homing peptide CREKA functionalised BNNTs (BNNTs-CREKA) effects on 4T1 tumour cells. The in vivo analysis observed that a significant amount of BNNTs-CREKA piled up at the tumour to target the cells [32]. Furthermore, biodistribution studies were conducted in mice after injecting radioactive 99m-BNNTs-CREKA [32]. The radioactivity biodistribution was assessed by an automatic scintillation counter in liver, spleen, kidneys, stomach, thyroid, heart, intestines, tumour, and muscle after exposure for up to 8 h with organs removed from mice [32]. It was observed that the tumour uptake was higher compared to non-targeted tissues such as muscle, intestines, heart, and thyroid, while the uptake was higher in liver, spleen, and kidney due the macrophages present in these organs after exposure [32]. Similarly, Nakamura et al. [39] synthesised BNNTs functionalised with DSPE-PEG2000 to investigate antitumour outcomes on B16 melanoma cells [59]. The results indicated that BNNTs-DSPE-PEG2000 showed higher antitumour effects in B16 cells [59].

In another study, Danti et al. [56] presented an interesting analysis on BNNT functionalised muscle-cell microfibre-mesh scaffolds acquired through a tissue-engineering three-dimensional (3D) platform to study a wireless stimulation system for electrically responsive cells and tissues [56]. The scaffolds were seeded with C2C12 myoblast cells under low ultrasound (US) irradiation [56]. The results stated that the cells’ interaction with BNNTs increased gene (Cx43) expression in 3D samples. Additionally, the higher protein levels of Cx43 and myosin were detected in the 3D scaffold model. The findings indicated that there was potential for developing appropriate in vitro platforms for biological modelling [56].
3.6.13. In Vitro Studies Stated BNNTs Are Cytotoxic

The above-mentioned studies were generally in favour of BNNTs biocompatibility. However, there are debatable results about their toxicity in the literature. Horvath et al. [74] highlighted the toxicity of pure BNNTs, which were dispersed with Tween 80 on various cell lines, such as lung epithelium cells, mouse macrophage cells, mouse embryonic fibroblasts, and HEK 293, with a maximum BNNT concentration of 20 µg·mL⁻¹ [74]. Various viability assessments were performed and cytotoxic effects at a minimal dose of BNNTs incubated with cells was noticed [74]. The study highlighted the size and aspect ratio and absence of biomolecules that lead to higher toxicity levels in cell cultures [74]. Augustine et al. [37] investigated a novel atomic force microscopy (AFM)-based cardiomyocyte assay that reliably assesses the cytotoxicity of BNNTs. High-energy probe sonication was used to modify and control the length of BNNTs [37]. Cytotoxicity studies using the novel cardiomyocyte AFM model agreed with traditional colorimetric cell metabolic assays, both revealing a correlation between tube length and cytotoxicity with longer tubes having higher cytotoxicity [37]. In addition to the size-dependent cytotoxicity, it was found that BNNTs exhibited concentration- and cell-line-dependent cytotoxic effects [37]. Çal et al. [35] demonstrated the cytotoxicity and DNA damage effects of BNNTs and curcumin using HeLa cells, CD34+ cells, and V79 cells. The MTT and Comet assay indicated that curcumin and BNNTs-curcumin were cytotoxic in all the concentrations [35]. Furthermore, the increase in ROS caused DNA damage to cells treated with BNNTs. The results stated that curcumin and BNNTs-curcumin concentration groups were similar, which may be a sign of the BNNTs inertness [35].

Overall, the results of BNNTs in in vitro toxicology depend on the purity, functionalisation, and geometrical dimensions of BNNTs. Taken together, all the literature on in vitro assessment of BNNTs showed good biocompatibility. The biocompatibility data for in vitro conditions reported thus far (on various cell lines) stated that BNNTs are potential nanomaterials for nanovectors, therapeutic, and biomedical applications although further in vivo and clinical analysis is needed.

3.7. BNNTs Biocompatibility In Vivo

The biocompatibility of BNNTs should be further assessed to identify the toxicity levels to tissue at the organism level through in vivo studies. The in vivo studies have been conducted using BNNTs, either pristine or functionalised, and various dispersion agents injected/fed into the animals. The animals were generally injected or fed with various dosages of BNNTs to investigate the toxicity levels or unusual inflammation reactions in their Airways or blood or distribution of BNNTs in the organisms.

To date, in vivo assessment of BNNTs is very limited. An initial pilot study was carried out by Ciofani et al. [72] which was performed with BNNT-GC (1 mg·mL⁻¹) injected into the marginal ear veins of five rabbits [72]. The blood tests were performed up to 72 h after injection and compared with plain GC (1 mg·mL⁻¹) solution [72]. The results stated that there was no alteration of the basic hematic parameters that could subvert the functional impairment of blood, liver, or kidneys [72]. No acute toxicity was observed after BNNTs-GC was injected into rabbits over the period [72]. In another investigation by Ciofani et al. [69], a higher dose of up to 10 mg·kg⁻¹ of GC-BNNTs was injected into the rabbits. Additionally, an assessment was performed after injecting 5 mg·kg⁻³ of GC-BNNTs once per day for three days [69]. The blood-analysis report showed no evidence of negative effects on blood or liver and there was no kidney impairment [69]. Furthermore, plasma pharmacokinetic studies indicated no significant temporary accumulation of BNNTs in tissues that could act as reversible reservoirs [69]. Collectively, these data suggest a relatively high clearance of BNNTs from the blood and a quick distribution in the organism and/or excretion [69].

Soares et al. [71] demonstrated BNNTs functionalised with GC and radiolabelled with ⁹⁹ᵐTc and injected into Swiss mice tails in order to evaluate their biodistribution. The results showed that, after 24 h, GC-BNNTs had accumulated in the liver, spleen, and gut, and had been eliminated via renal excretion (Figure 8) [71].
Salvetti et al. [57] reported the effects of BNNTs on stem cells and tissue regeneration in planarians. BNNTs coated with GA were injected into planarians at concentrations of 100 or 200 µg·g\(^{-1}\) for 15 days [57]. It was stated that GA-BNNTs were internalised by intestinal cells within 1 day after injection and did not induce any DNA damage in animals [57]. However, the study failed to detect the difference in expression levels of molecular markers specific to stem cells and stem-cell progenies that indicate BNNTs effects in stem cells [57]. The study found no adverse effects on neoblasts, which are essential for tissue regeneration [57]. Furthermore, the analysis stated that GA-BNNTs did not show any effects in the morphogenetic process [57].

Demir et al. [40] studied the antioxidant/antigenotoxic properties of BNNTs using drosophila melanogaster. The analysis stated that non-relevant genotoxic effects were observed in the wing-spot assay or in the Comet test [40]. Furthermore, it was observed that BNNTs significantly reduced the genotoxic effect of potassium dichromate (PDC) and the intracellular levels of ROS, which indicates the non-toxic effects of BNNTs [40].

In contrast to the above studies, Xin et al. [29] reported the toxicity of BNNTs after being exposed to lung cells, using an in vivo time-course model. The in vivo studies were performed on male C57BL/6J mice with BNNTs (~50% purity) at 200 µm length and 5 nm width (Figure 9) [29]. BNNTs at 4 and 40 µg concentrations were exposed for 4 h, 1, 4, and 7 d, 1 and 2 months to mice (lungs) to measure and evaluate pulmonary and extrapulmonary toxicity [29]. Bronchoalveolar lavage (BAL) was utilised on the BNNTs-exposed mice to collect fluid and BAL cells to demonstrate the toxicity [29]. The results indicated that high doses of BNNTs considerably enhanced the lactate dehydrogenase activity (LDH) from 4 h to 7 d post exposure, compared to low dose and control groups [29]. However, the low dose of BNNTs did not show any significant lung injury as indicated by LDH activity throughout the time points [29]. Furthermore, the cells displayed a minimal level of inflammation in the high-dose group with resolution over time and no fibrosis [29]. In addition, the lung-clearance analysis observed that ~50% of the BNNTs cleared over the time period [29]. The lung gene expression of Cxcl2, Ccl2, Il6, Ccl22, Ccl11 and Spp1 was considerably increased, 4 h and 1 d after exposure at 40 µg [29]. However, the inflammation and acute-phase gene expression decreased over the times [29]. Interestingly, 4 µg BNNTs did not show any unfavourable effects in the toxicity results, post exposure [29]. Thus, it was determined that high doses of BNNTs showed acute pulmonary inflammation and injury after 7 days of exposure [29].

**Figure 8.** Scintigraphic image of radiographic GC-BNNTs biodistribution in mice; (a–c) show the images after injecting at time intervals of 30 min, 1, and 4 h, respectively. Reproduced with permission from Ref. [71]. Copyrights 2012, Elsevier.
Similarly, Kodali et al. [45] reported acute toxicity both in vitro and in vivo using commercial-grade BNNTs, which are composed of ∼50–60% BNNTs and ∼40–50% impurities of boron and hexagonal boron nitride. The studies were conducted both in vitro (using THP-1 and NLRP-3 cells) and by injecting 40 µg of BNNTs into male mice [45]. The in vitro studies stated that the BNNTs exhibited dose-dependent acute toxicity and oxidative stress [45]. The results were further confirmed with in vivo tests following a BNNTs exposure, with an increase in bronchoalveolar lavage levels of LDH, a pulmonary polymorphonuclear cell influx, loss in mitochondrial membrane potential, and higher accumulation levels of 4-hydroxynonenal [45]. Additionally, cytokine analysis displayed acute inflammation following the exposure of BNNTs to both cells and in vivo [45].

To summarise, based on the reports available, it was evident that the as-synthesised BNNTs with impurities cause acute toxicity in vivo as well as in vitro. Furthermore, BNNTs functionalised with various materials showed cytocompatibility up to a maximum concentration of 100 µg·mL⁻¹. However, further in-depth analysis of BNNTs in various in vivo aspects could give a better understanding of BNNT biocompatibility.

4. Biomedical and Tissue-Engineering Applications

Due to their interesting physiochemical properties, BNNTs have been gaining significant attention from researchers and industries. In biomedical and tissue-engineering applications, when BNNTs are functionalised with various organic and inorganic materials, non-toxicity is reported, up to dosage levels of 100 µg·mL⁻¹. Thus far, some of the studies have suggested applications of BNNTs in cancer-tumour treatment [32,61,80], drug carries or drug delivery [30], radioisotope accumulation of tumours [31], MRI contrast agents [68,73], reinforcement for biomaterials to produce tissue scaffolds [53,56], orthopaedic procedures [75,77], dental procedures [41,62], bioimaging [158], and bioprinting [24,25]. Not only are there biocompatibility properties but there are also amazing piezoelectrical properties, leading some to propose BNNTs as nanotransducers for the electrical stimulation of cells [39,56].

4.1. Boron Neutron Capture Therapy (BNCT)

Cancer is one of the significant causes of death in humans worldwide. Researchers have focused on finding a novel material for targeting the tumour cells with radiation therapy and chemotherapy. In this regard, BNNTs have been investigated as potential material to target cancer cells. For instance, Li et al. [28] demonstrated the Auristatin-PE-coated BNNTs as a drug delivery system to act against the liver cancer cells. The outcomes stated that the PE-BNNTs killed tumour cells and showed promise for treating liver cancer. Furthermore, Li et al. [61] stated that BNNTs@NaGdF₄:Eu was a possible material with the ability to use in chemotherapy drug delivery systems in the presence of a magnetic field. Similarly, Nakamura et al. [59] stated that functionalised BNNTs displayed a higher accumulation of tumour cells with a combination of thermal neutron irradiation on BNCT.
4.2. Nanovectors

Recent evaluations on the interaction between the BNNTs with living cells confirmed BNNTs as promising nanovectors for various applications in biomedicine; for instance, PEI-coated BNNTs combined with fluorescent markers demonstrated as nanovectors for cell therapy by tracking their uptake by SHY-SY5Y cell lines [83]. Similarly, PLL-BNNTs were demonstrated as nanovectors that can enter the cells when exposed to the electroporation to a 40–60 V cm\(^{-1}\) electric field.

4.3. Tissue Engineering

Recent studies demonstrated that BNNTs combined with various polymeric materials can be used as scaffolds for tissue engineering applications. The scaffolds can be developed using various tissue engineering techniques such as electrospinning or additive manufacturing. For instance, BNNTs combined with co-polymer PLC films were demonstrated as scaffolds for orthopaedic applications with excellent mechanical and biocompatible properties [77]. Similarly, BNNTs combined with resin-based dental sealants showed potential materials in therapeutic procedures of dental hard tissues [34]. In another study, Kakarla et al. demonstrated that BNNTs reinforced gelatine and alginate as a hydrogel to produce hydrogel scaffolds for tissue engineering applications [24,25].

Most of the biocompatibility analysis findings with BNNTs' interaction with different live cells have provided more profound insights. Taken all together, the studies have reported that BNNTs are a promising nanomaterial for biomedical and tissue-engineering applications.

5. Summary and Outlook

The selection of suitable biomaterials for applications in biomedical research is often associated with the materials’ interactions with living matter. Therefore, the biosafety and biological properties of the material must be considered. Regarding the use of BNNTs, the exploitation of biological properties and interactions with various cell lines and living matter is still at the entry level. A number of challenges still need to be addressed before BNNTs are validated for clinical applications. One of the major issues is BNNTs insolubility in aqueous media. Various organic and inorganic materials have been reported for the functionalisation of BNNTs to obtain stabilised and dispersible BNNTs in aqueous media. However, only a few biomolecules and biocompatible materials have been explored in functionalised BNNTs. Therefore, a wide range of BNNTs (functionalised with various biomaterials or biomolecules) need to be evaluated in vivo and in vitro to understand the toxicity levels. Another major aspect is to find BNNTs toxicity in the living body. Thus far, only a few studies have reported on living-body experiments with commercially available BNNTs and functionalised BNNTs. The results are contradictory, as the studies are limited. Hence, further studies focused on BNNTs in various living organisms and the effects on tissues and organs could help to increase the potential biomedical application of BNNTs.

For instance, as an innovative nanomaterial, BNNTs show a great range of promising results in cancer treatments, especially in boron-neutron cancer treatment. Additionally, BNNTs aid in increasing bright fields in MRI and creating piezoelectrical material to stimulate cells—these show potential for biomedical applications. However, it was reported that BNNTs with impurities (composed during synthesis or catalyst) displayed acute toxicity under in vitro and in vivo conditions. Thus, it is mandatory to address the influence on cytotoxicity of the impurities or catalysts used in the synthesis of BNNTs.

In summary, the data as a whole suggested that BNNTs with various functionalised materials were not cytotoxic in concentrations up to 100 \(\mu\)g mL\(^{-1}\). Furthermore, the results confirmed the high potential of BNNTs in various biomedical and tissue-engineering applications. Simultaneously, it was reported that BNNTs are able to address cell behaviour and probe morphological and functional signatures of tumours. However, the candidacy of BNNTs as being optimal for an impressive variety of applications in the biomedical domain needs to be explored more. The biocompatibility of BNNTs under in vivo conditions needs
to be assessed further to address biosafety in living organisms. This could pave the way to significant progress in pharmacology, nanomedicine, and even in clinical research.

**Author Contributions:** Conceptualisation, A.B.K. and I.K.; methodology, A.B.K. and I.K.; validation, A.B.K. and I.K.; formal analysis, A.B.K. and I.K.; investigation, A.B.K. and I.K.; resources, A.B.K. and I.K.; data curation, A.B.K. and I.K.; writing—original draft preparation, A.B.K.; writing—review and editing, I.K.; supervision, I.K.; project administration, I.K.; funding acquisition, I.K. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** Not applicable.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Rubio, A.; Corkill, J.L.; Cohen, M.L. Theory of graphitic boron nitride nanotubes. *Phys. Rev. B* **1994**, *49*, 5081–5084. [CrossRef] [PubMed]
2. Blase, X.; Rubio, A.; Louie, S.G.; Cohen, M.L. Stability and Band Gap Constancy of Boron Nitride Nanotubes. *Europhys. Lett.* **1994**, *28*, 335–340. [CrossRef]
3. Chopra, N.G.; Luyken, R.J.; Cherrey, K.; Crespi, V.H.; Cohen, M.L.; Louie, S.G.; Zettl, A. Boron Nitride Nanotubes. *Science* **1995**, *269*, 966–967. [CrossRef]
4. Golberg, D.; Bando, Y.; Huang, Y.; Terao, T.; Mitome, M.; Tang, C.; Zhi, C. Boron Nitride Nanotubes and Nanosheets. *ACS Nano* **2010**, *4*, 2979–2993. [CrossRef] [PubMed]
5. Lee, C.H.; Xie, M.; Kayastha, V.; Wang, J.; Yap, Y.K. Patterned Growth of Boron Nitride Nanotubes by Catalytic Chemical Vapor Deposition. *Chem. Mater.* **2010**, *22*, 1782–1787. [CrossRef]
6. Chen, H.; Chen, Y.; Liu, Y.; Fu, L.; Huang, C.; Llewellyn, D. Over 1.0 mm-long boron nitride nanotubes. *Chem. Phys. Lett.* **2008**, *463*, 130–133. [CrossRef]
7. Golberg, D.; Han, W.; Bando, Y.; Bourgeois, L.; Kurashima, K.; Sato, T. Fine structure of boron nitride nanotubes produced from carbon nanotubes by a substitution reaction. *J. Appl. Phys.* **1999**, *86*, 2364–2366. [CrossRef]
8. Bi, X.; Yin, Y.; Li, J.; Chen, Y.; Li, J.; Su, Q. A co-precipitation and annealing route to the large-quantity synthesis of boron nitride nanotubes. *Solid State Sci.* **2013**, *25*, 39–44. [CrossRef]
9. Zhi, C.; Bando, Y.; Tang, C.; Golberg, D. Boron nitride nanotubes. *Mater. Sci. Eng. R Rep.* **2010**, *70*, 92–111. [CrossRef]
10. Köken, D.; Sungur, P.; Cebeci, H.; Cebeci, F.C. Revealing the Effect of Sulfur Compounds for Low-Temperature Synthesis of Boron Nitride Nanotubes from Boron Minerals. *ACS Appl. Nano Mater.* **2022**, *5*, 2137–2146. [CrossRef]
11. TARHAN, T. Synthesis and characterization of boron nitride nanotubes (BNNTs) with a new method and precursor materials. *Gümüşhane Üniversitesi Fen Bilim. Enstitüsü Derg.* **2021**, *11*, 1217–1224. [CrossRef]
12. Wang, J.; Lee, C.H.; Yap, Y.K. Recent advancements in boron nitride nanotubes. *Nanoscale* **2010**, *2*, 2028. [CrossRef] [PubMed]
13. Chopra, N.G.; Zettl, A. Measurement of the elastic modulus of a multi-wall boron nitride nanotube. *Solid State Commun.* **1998**, *105*, 297–300. [CrossRef]
14. Golberg, D.; Bando, Y.; Kurashima, K.; Sato, T. Synthesis and characterization of ropes made of [BN] multiwalled nanotubes. *Scr. Mater.* **2001**, *44*, 1561–1565. [CrossRef]
15. Chang, C.W.; Fennimore, A.M.; Afanasiev, A.; Okawa, D.; Ikuno, T.; Garcia, H.; Li, D.; Majumdar, A.; Zettl, A. Isotope Effect on the Thermal Conductivity of Boron Nitride Nanotubes. *Phys. Rev. Lett.* **2006**, *97*, 085901. [CrossRef] [PubMed]
16. Golberg, D.; Bando, Y.; Tang, C.C.; Zhi, C.Y. Boron Nitride Nanotubes. *Adv. Mater.* **2007**, *19*, 2413–2432. [CrossRef]
17. Bai, X.; Golberg, D.; Bando, Y.; Zhi, C.; Tang, C.; Mitome, M.; Kurashima, K. Deformation-Driven Electrical Transport of Individual Boron Nitride Nanotubes. *Nano Lett.* **2007**, *7*, 632–637. [CrossRef]
18. Lee, C.; Bhandari, S.; Tiwari, B.; Yapici, N.; Zhang, D.; Yap, Y. Boron Nitride Nanotubes: Recent Advances in Their Synthesis, Functionalization, and Applications. *Molecules* **2016**, *21*, 922. [CrossRef]
19. Ghazizadeh, M.; Estevez, J.E.; Kelkar, A.D. Boron Nitride Nanotubes for Space Radiation Shielding. *Int. J. Nano Stud. Technol.* **2015**, *4*, 1–2. [CrossRef]
20. Piazza, V.; Gemmi, M. Optical properties of boron nitride nanotubes: Potential exploitation in nanomedicine. In *Boron Nitride Nanotubes in Nanomedicine*; Elsevier: Amsterdam, The Netherlands, 2016; pp. 139–147. [CrossRef]
21. Lee, S.-H.; Kim, M.J.; Ahn, S.; Koh, B. Purification of Boron Nitride Nanotubes Enhances Biological Application Properties. *Int. J. Mol. Sci.* **2020**, *21*, 1529. [CrossRef]
23. Lee, C.H.; Zhang, D.; Yap, Y.K. Functionalization, Dispersion, and Cutting of Boron Nitride Nanotubes in Water. J. Phys. Chem. C 2012, 116, 1798–1804. [CrossRef]

24. Kakarla, A.B.; Kong, I.; Turek, I.; Kong, C.; Irving, H. Printable gelatin, alginate and boron nitride nanotubes hydrogel-based ink for 3D bioprinting and tissue engineering applications. Mater. Des. 2022, 213, 110362. [CrossRef]

25. Kakarla, A.B.; Kong, I.; Kong, C.; Irving. H. Extrusion-Based Bioprinted Boron Nitride Nanotubes Reinforced Alginate Scaffolds: Mechanical, Printability and Cell Viability Evaluation. Polymers 2022, 14, 486. [CrossRef] [PubMed]

26. Evariste, L.; Flahaut, E.; Baratange, C.; Barret, M.; Mouchet, F.; Pinelli, E.; Galibert, A.M.; Soula, B.; Gauthier, L. Ecotoxicological assessment of commercial boron nitride nanotubes toward Xenopus laevis tadpoles and host-associated gut microbiota. Nanotoxicology 2021, 15, 35–51. [CrossRef] [PubMed]

27. Li, W.; Xie, X.; Wu, T.; Yang, H.; Peng, Y.; Luo, L.; Chen, Y. Targeted delivery of Auristatin PE to Hep G2 cells using folate-conjugated boron nitride nanotubes. Mater. Sci. Eng. C 2020, 109, 110509. [CrossRef]

28. Li, W.; Xie, X.; Wu, T.; Lin, H.; Luo, L.; Yang, H.; Li, J.; Xin, Y.; Lin, X.; Chen, Y. Loading Auristatin PE onto boron nitride nanotubes and their effects on the apoptosis of Hep G2 cells. Colloids Surfaces B Biointerfaces 2019, 181, 305–314. [CrossRef]

29. Xin, X.; Barger, M.; Roach, K.A.; Bowers, L.; Stefaniak, A.B.; Kodali, V.; Glassford, E.; Dunn, K.H.L.; Dunn, K.H.L.; Wolfarth, M.; et al. Toxicity evaluation following pulmonary exposure to an as-manufactured dispersed boron nitride nanotube (BNNT) material in vivo. Nanomaterials 2020, 10, 10934. [CrossRef] [PubMed]

30. De Pasqua, D.; Marino, A.; Tapeinos, C.; Fucic, C.; Rocchiccioli, S.; Michelucci, E.; Finamore, F.; McDonnell, L.; Scarpellini, A.; Lauciello, S.; et al. Homotypic targeting and drug delivery in glioblastoma cells through cell membrane-coated boron nitride nanotubes. Mater. Des. 2020, 202, 108742. [CrossRef]

31. da Silva, W.M.; de Andrade Alves e Silva, R.H.; Cipresto, M.F.; Andrade, G.F.; Gastelois, P.L.; de Almeida Macedo, W.A.; de Sousa, E.M.B. Boron nitride nanotubes radiolabeled with 153Sm and 159Gd: Potential application in nanomedicine. Appl. Radiat. Isot. 2020, 157, 109602. [CrossRef]

32. Ferreira, T.H.; Ferreira, T.H.; de Oliveira Freitas, L.B.; Fernandes, R.S.; dos Santos, V.M.; Resende, J.M.; Cardoso, V.N.; de Barros, A.L.B.; de Sousa, E.M.B. Boron nitride nanotube-CREKA peptide as an effective target system to metastatic breast cancer. J. Pharm. Investig. 2020, 50, 469–480. [CrossRef]

33. Ferreira, C.; Leitune, V.; Balbinot, G.; Degrazia, F.; Arakelian, M.; Sauro, S.; Mezzomo Collares, F. Antibacterial and Remineralizing Fillers in Experimental Orthodontic Adhesives. Materials 2019, 12, 652. [CrossRef] [PubMed]

34. Bohns, F.R.; Degrazia, F.W.; Leitune, V.C.B.; Samuel, S.M.W.; García-Esparza, M.A.; Sauro, S.; Collares, F.M. Boron Nitride Nanotubes as Filler for Resin-Based Dental Sealants. Sci. Rep. 2019, 9, 7710. [CrossRef] [PubMed]

35. Cal, T.; Bucurăt, U. U. In vitro investigation of the effects of boron nitride nanotubes and curcumin on DNA damage. DARU J. Pharm. Sci. 2019, 27, 203–218. [CrossRef] [PubMed]

36. Ricotti, L.; Fujie, T.; Važao, H.; Ciofani, G.; Marotta, R.; Piccarreta, D.; et al. Toxicity evaluation following pulmonary exposure to an as-manufactured dispersed boron nitride nanotube (BNNT) material in vivo. Nanomaterials 2020, 10, 10934. [CrossRef] [PubMed]

37. Augustine, J.; Cheung, T.; Gies, V.; Boughton, J.; Chen, M.; Jakubek, Z.J.; Walker, S.; Martinez-Rubi, Y.; Zou, S. Assessing size-dependent cytotoxicity of boron nitride nanotubes using a novel cardiomyocyte AFM assay. Nanoscale Adv. 2019, 1, 1914–1923. [CrossRef]

38. Poudel, A.; Fernandez, M.A.; Tofail, S.A.M.; Biggs, M.J.P. Boron Nitride Nanotube Addition Enhances the Crystallinity and Cytocompatibility of PVDF-TrFE. Front. Chem. 2019, 7, 364. [CrossRef] [PubMed]

39. Genchi, G.G.; Sinibaldi, E.; Cesaracciu, L.; Labardi, M.; Marino, A.; Marras, S.; De Simoni, G.; Mattoli, V.; Ciofani, G. Ultrasound-activated piezoelectric P(VDF-TrFE)/boron nitride nanotube composite films promote differentiation of human SaOS-2 osteoblast-like cells. Nanomed. Nanotechnol. Biol. Med. 2018, 14, 2421–2432. [CrossRef]

40. Demir, E.; Marcos, R. Antigenotoxic potential of boron nitride nanotubes. Nanotoxicology 2012, 18, 868–884. [CrossRef]

41. Degrazia, F.W.; Leitune, V.C.B.; Visioli, F.; Samuel, S.M.W.; Collares, F.M. Long-term stability of dental adhesive incorporated by boron nitride nanotubes. Dent. Mater. 2018, 34, 427–433. [CrossRef]

42. Ferreira, T.H.; Faria, J.A.Q.A.; Gonzalez, I.J.; Outo, L.E.F.; Macedo, W.A.A.; Gomes, D.A.; Sousa, E.M.B. BNNT/Fe3O4 System as an Efficient Tool for Magnetohyperthermia Therapy. J. Nanosci. Nanotechnol. 2018, 18, 6746–6755. [CrossRef] [PubMed]

43. Ferreira, T.; Miranda, M.; Rocha, Z.; Leal, A.; Gomes, D.; Sousa, E. An Assessment of the Potential Use of BNNTs for Boron Neutron Capture Therapy. Nanomaterials 2017, 7, 82. [CrossRef] [PubMed]

44. Ponraj, S.B.; Chen, Z.; Li, L.H.; Shankaranarayanan, J.S.; Rajmohan, G.D.; du Plessis, J.; Sinclair, A.J.; Chen, Y.; Wang, X.; Kanwar, J.R.; et al. Fabrication of Boron Nitride Nanotube–Gold Nanoparticle Hybrids Using Pulsed Plasma in Liquid. Langmuir 2014, 30, 10712–10720. [CrossRef]

45. Kodali, V.K.; Roberts, J.R.; Shoeb, M.; Wolfarth, M.G.; Bishop, L.; Eye, T.; Barger, M.; Roach, K.A.; Friend, S.; Schweger-Berry, D.; et al. Acute in vitro and in vivo toxicity of a commercial grade boron nitride nanotube mixture. Nanotoxicology 2017, 11, 1040–1058. [CrossRef] [PubMed]

46. Şen, O.; Coşbundede, Z.; Emanet, M.; Bayrak, Ó.F.; Culha, M. Boron nitride nanotubes for gene silencing. Biochim. Biophys. Acta -Gen. Subj. 2017, 1861, 2391–2397. [CrossRef] [PubMed]
47. Farshid, B.; Lalwani, G.; Shir Mohammadi, M.; Simonsen, J.; Sitharaman, B. Boron nitride nanotubes and nanoplatelets as reinforcing agents of polymeric matrices for bone tissue engineering. *J. Biomed. Mater. Res. Part B Appl. Biomater.* 2017, 105, 406–419. [CrossRef]

48. Emanet, M.; Kazanc, E.; Çobandede, Z.; Culha, M. Boron nitride nanotubes enhance properties of chitosan-based scaffolds. *Carbohydr. Polym.* 2016, 151, 313–320. [CrossRef]

49. Rocca, A.; Marino, A.; Del Turco, S.; Cappello, V.; Parlanti, P.; Pellegrino, M.; Golberg, D.; Mattoli, V.; Ciofani, G. Pectin-coated boron nitride nanotubes: In vitro cyto-/immune-compatibility on RAW 264.7 macrophages. *Biochim. Biophys. Acta-Gen. Subj.* 2016, 1860, 775–784. [CrossRef]

50. Niskanen, J.; Zhang, L.; Xue, Y.; Golberg, D.; Maysinger, D.; Winnik, F.M. Boron nitride nanotubes as vehicles for intracellular delivery of fluorescent drugs and probes. *Nanomedicine* 2011, 11, 447–463. [CrossRef]

51. Şen, O.; Culha, M. Boron nitride nanotubes included thermally cross-linked gelatin–glucose scaffolds show improved properties. *Colloids Surf. B Biointerfaces* 2016, 138, 41–49. [CrossRef]

52. Li, X.; Wang, X.; Jiang, X.; Yamaguchi, M.; Ito, A.; Bando, Y.; Golberg, D. Boron nitride nanotube-enhanced osteogenic differentiation of mesenchymal stem cells. *J. Biomed. Mater. Res. Part B Appl. Biomater.* 2016, 104, 323–329. [CrossRef] [PubMed]

53. Diez-Pascual, A.M.; Diez-Vicente, A.L. PEGylated boron nitride nanotube-reinforced poly(propylene fumarate) nanocomposite biomaterials. *RSC Adv.* 2016, 6, 79507–79519. [CrossRef]

54. Fernandez-Yague, M.A.; Larrañaga, A.; Gladkovskaya, O.; Stanley, A.; Tadayyon, G.; Guo, Y.; Sarasua, J.-R.; Tofail, S.A.M.; Zeugolis, D.J.; Pandit, A.; et al. Effects of Polydopamine Functionalization on Boron Nitride Nanotube Dispersion and Cytocompatibility. *Bioconjug. Chem.* 2015, 26, 2025–2037. [CrossRef]

55. Emanet, M.; Sen, Ö.; Çobandede, Z.; Culha, M. Interaction of carbohydrate modified boron nitride nanotubes with living cells. *Colloids Surf. B Biointerfaces* 2015, 134, 440–446. [CrossRef] [PubMed]

56. Danti, S.; Ciofani, G.; Pertici, G.; Moscati, S.; D’Alessandro, D.; Ciabatti, E.; Chelli, F.; D’Acunto, M.; Mattoli, V.; Berrettini, S. Boron nitride nanotube-functionalised myoblast/microfibre constructs: A nanotech-assisted tissue-engineered platform for muscle stimulation. *J. Tissue Eng. Regen. Med.* 2015, 9, 847–851. [CrossRef]

57. Salvetti, A.; Rossi, L.; Iaccopetti, P.; Li, X.; Nitti, S.; Pellegrino, T.; Mattoli, V.; Golberg, D.; Ciofani, G. In vivo biocompatibility of boron nitride nanotubes: Effects on stem cell biology and tissue regeneration in planarians. *Nanomedicine* 2015, 10, 1911–1922. [CrossRef]

58. Ferreira, T.H.; Marino, A.; Rocca, A.; Liakos, I.; Nitti, S.; Athanassiou, A.; Mattoli, V.; de Sousa, E.M.B.; Ciofani, G. Folate-grafted boron nitride nanotubes: Possible exploitation in cancer therapy. *Int. J. Pharm.* 2015, 481, 56–63. [CrossRef]

59. Nakamura, H.; Koganei, H.; Miyoshi, T.; Sakurai, Y.; Ono, K.; Suzuki, M. Antitumor effect of boron nitride nanotubes in combination with thermal neutron irradiation on BNCT. *Biorg. Med. Chem. Lett.* 2015, 25, 172–174. [CrossRef]

60. Ferreira, T.H.; Rocca, A.; Marino, A.; Mattoli, V.; de Sousa, E.M.B.; Ciofani, G. Evaluation of the effects of boron nitride nanotubes functionalized with mesoporous silica on the differentiation of rat mesenchymal stem cells. *RSC Adv.* 2015, 5, 45431–45438. [CrossRef]

61. Li, X.; Hanagata, N.; Wang, X.; Yamaguchi, M.; Yi, W.; Bando, Y.; Golberg, D. Multimodal luminescent-magnetic boron nitride nanotubes@NaGdF 4: Eu structures for cancer therapy. *Chem. Commun.* 2014, 50, 4371–4374. [CrossRef]

62. Barachini, S.; Danti, S.; Pacini, S.; D’Alessandro, D.; Carnicelli, V.; Trombi, L.; Moscati, S.; Mannari, C.; Cei, S.; Petruni, M. Plasticity of human dental pulp stromal cells with bioengineering platforms: A versatile tool for regenerative medicine. *Micron* 2014, 67, 155–168. [CrossRef] [PubMed]

63. Maria Nithya, J.S.; Pandurangan, A. Aqueous dispersion of polymer coated boron nitride nanotubes and their antibacterial and cytotoxicity studies. *RSC Adv.* 2014, 4, 32031–32046. [CrossRef]

64. Ciofani, G.; Del Turco, S.; Rocca, A.; de Vito, G.; Cappello, V.; Yamaguchi, M.; Li, X.; Mazzolai, B.; Basta, G.; Gemmi, M.; et al. Cytocompatibility evaluation of gum Arabic-coated ultra-pure boron nitride nanotubes on human cells. *Nanomedicine* 2014, 9, 773–788. [CrossRef] [PubMed]

65. Ferreira, T.H.; Soares, D.C.F.; Moreira, L.M.C.; da Silva, P.R.O.; dos Santos, R.G.; de Sousa, E.M.B. Boron nitride nanotubes coated with organic hydrophilic agents: Stability and cytocompatibility studies. * Mater. Sci. Eng. C* 2013, 33, 4616–4623. [CrossRef] [PubMed]

66. Danti, S.; Ciofani, G.; Moscati, S.; D’Alessandro, D.; Ciabatti, E.; Nesti, C.; Brescia, R.; Bertoni, G.; Pietrabissa, A.; Lisanti, M.; et al. Boron nitride nanotubes and primary human osteoblasts: In vitro compatibility and biological interactions under low frequency ultrasound stimulation. *Nanotechnology* 2013, 24, 465102. [CrossRef] [PubMed]

67. Del Turco, S.; Ciofani, G.; Cappello, V.; Gemmi, M.; Cervelli, T.; Saponaro, C.; Nitti, S.; Mazzolai, B.; Basta, G.; Mattoli, V. Cytocompatibility evaluation of glycol-chitosan coated boron nitride nanotubes in human endothelial cells. *Colloids Surfaces B Biointerfaces* 2013, 111, 142–149. [CrossRef]

68. Ciofani, G.; Boni, A.; Calucci, L.; Forte, C.; Gozzi, A.; Mazzolai, B.; Mattoli, V. Gd-doped BNNTs as T 2-weighted MRI contrast agents. *Nanotechnology* 2013, 24, 315101. [CrossRef]

69. Ciofani, G.; Danti, S.; Nitti, S.; Mazzolai, B.; Mattoli, V.; Giorgi, M. Biocompatibility of boron nitride nanotubes: An up-date of in vivo toxicological investigation. *Int. J. Pharm.* 2013, 444, 85–88. [CrossRef]

70. Ciofani, G.; Genchi, G.G.; Liakos, I.; Athanassiou, A.; Dinucci, D.; Chelli, F.; Mattoli, V. A simple approach to covalent functionalization of boron nitride nanotubes. *J. Colloid Interface Sci.* 2012, 374, 308–314. [CrossRef]
71. Soares, D.C.F.; Ferreira, T.H.; de Aguiar Ferreira, C.; Cardoso, V.N.; de Sousa, E.M.B. Boron nitride nanotubes radiolabeled with 99mTc: Preparation, physicochemical characterization, biodistribution study, and scintigraphic imaging in Swiss mice. *Int. J. Pharm.* 2012, 423, 489–495. [CrossRef]

72. Cicofani, G.; Graziana, G.G.; Mattoli, V.; Danti, S.; Giorgi, M. Pilot in vivo toxicological investigation of boron nitride nanotubes. *Int. J. Nanomed.* 2012, 7, 19. [CrossRef] [PubMed]

73. Menichetti, L.; De Marchi, D.; Calucci, L.; Cicofani, G.; Menciassi, A.; Forte, C. Boron nitride nanotubes for boron neutron capture therapy as contrast agents in magnetic resonance imaging at 3T. *Appl. Radiat. Isot.* 2011, 69, 1725–1727. [CrossRef] [PubMed]

74. Horváth, L.; Magrez, A.; Golberg, D.; Zhi, C.; Bando, Y.; Smajda, R.; Horváth, E.; Forró, L.; Schwaller, B. *In Vitro* Investigation of the Cellular Toxicity of Boron Nitride Nanotubes. *ACS Nano* 2011, 5, 3800–3810. [CrossRef] [PubMed]

75. Lahiri, D.; Singh, V.; Benaduce, A.P.; Seal, S.; Kos, L.; Agarwal, A. Boron nitride nanotube reinforced hydroxyapatite composite: Mechanical and tribological performance and in-vitro biocompatibility to osteoblasts. *J. Mech. Behav. Biomater.* 2011, 4, 44–56. [CrossRef]

76. Cicofani, G.; Danti, S.; D’Alessandro, D.; Moscato, S.; Menciassi, A. Assessing cytotoxicity of boron nitride nanotubes: Interference with the MIT assay. *Biochem. Biophys. Res. Commun.* 2010, 394, 405–411. [CrossRef]

77. Lahiri, D.; Rouzaud, F.; Richard, T.; Keshri, A.K.; Bakshi, S.R.; Kos, L.; Agarwal, A. Boron nitride nanotube reinforced poly lactide–polycaprolactone copolymer composite: Mechanical properties and cytocompatibility with osteoblasts and macrophages in vitro. *Acta Biomater.* 2010, 6, 3524–3533. [CrossRef]

78. Cicofani, G.; Ricotti, L.; Danti, S.; Moscato, S.; Nesti, C.; D’Alessandro, D.; Dinucci, D.; Chielini, F.; Pietrabissa, A.; Petriti, M.; et al. Investigation of interactions between poly-L-lysine-coated boron nitride nanotubes and C2C12 cells: Up-take, cytocompatibility, and differentiation. *Int. J. Nanomed.* 2010, 5, 285. [CrossRef]

79. RAFIA, V.; CIOFANI, G.; CUSCHIERI, A. Enhanced low voltage cell electroporation by boron nitride nanotubes. *Nanotechnology* 2009, 20, 075104. [CrossRef]

80. Cicofani, G.; RAFFA, V.; MENICIASSI, A.; CUSCHIERI, A. Folate Functionalized Boron Nitride Nanotubes and their Selective Uptake by Glioblastoma Multiforme Cells: Implications for their Use as Boron Carriers in Clinical Boron Neutron Capture Therapy. *Nanoscale Res. Lett.* 2009, 4, 113. [CrossRef]

81. CHEN, X.; WU, P.; ROUSSEAS, M.; OKAWA, D.; GARTNER, Z.; ZETTL, A.; BERTOZZI, C.R. Boron Nitride Nanotubes Are Noncytotoxic and Can Be Functionalized for Interaction with Proteins and Cells. *J. Am. Chem. Soc.* 2009, 131, 890–891. [CrossRef]

82. Cicofani, G.; RAFFA, V.; MENICIASSI, A.; CUSCHIERI, A. Cytocompatibility, interactions, and uptake of polyethyleneimine-coated boron nitride nanotubes by living cells: Confirmation of their potential for biomedical applications. *Biotechnol. Bioeng.* 2008, 101, 850–858. [CrossRef] [PubMed]

83. Cicofani, G.; RAFFA, V.; MENICIASSI, A.; DARIO, P. Preparation of Boron Nitride Nanotubes Aqueous Dispersions for Biological Applications. *J. Nanosci. Nanotechnol.* 2008, 8, 6223–6231. [CrossRef] [PubMed]

84. KIM, J.H.; PHAM, T.V.; HWANG, J.H.; KIM, C.S.; KIM, M.J. Boron nitride nanotubes: Synthesis and applications. *Nano Convoy.* 2018, 5, 17. [CrossRef] [PubMed]

85. CUMINGS, J.; ZETTL, A. Mass-production of boron nitride double-wall nanotubes and nanococoon. *Chem. Phys. Lett.* 2000, 316, 211–216. [CrossRef]

86. Saito, Y.; MAIDA, M.; MATSUMOTO, T. Structures of Boron Nitride Nanotubes with Single-Layer and Multilayers Produced by Arc Discharge. *Ipn. J. Appl. Phys.* 1999, 38, 159–163. [CrossRef]

87. YEH, Y.-W.; RAITSES, Y.; KOEL, B.E.; YAO, N. Stable synthesis of few-layered boron nitride nanotubes by anodic arc discharge. *Sci. Rep.* 2017, 7, 3075. [CrossRef]

88. CHEN, Y.; FITZ GERALD, J.; WILLIAMS, J.S.; BULCOCK, S. Synthesis of boron nitride nanotubes at low temperatures using reactive ball milling. *Chem. Phys. Lett.* 1999, 299, 260–264. [CrossRef]

89. CHEN, Y.; CUMINGS, J.; FITZ GERALD, J.; DARIO, P. A solid-state process for formation of boron nitride nanotubes. *Appl. Phys. Lett.* 1999, 74, 2960–2962. [CrossRef]

90. FITZ GERALD, J.D.; CHEN, Y.; CONWAY, M.J. Nanotube growth during annealing of mechanically milled Boron. *Appl. Phys. A* 2003, 76, 107–110. [CrossRef]

91. YONG BAE, S.; WON SEO, H.; PARK, J.; SANG CHOI, Y.; CHUL PARK, J.; YOUNG LEE, S. Boron nitride nanotubes synthesized in the temperature range 1000–1200◦C. *J. Eur. Ceram. Soc.* 2018, 38, 4614–4622. [CrossRef]

92. ZHUANG, C.-C.; FENG, J.; XU, H.; LI, L.; LIU, X.-W. Synthesis of boron nitride nanotube films with a nanoparticle catalyst. *Chinese Chem. Lett.* 2016, 27, 871–874. [CrossRef]

93. ZHU, G.; DONG, S.; HU, J.; KAN, Y.; HE, P.; GAO, L.; ZHANG, X.; ZHOU, H. In situ growth behavior of boron nitride nanotubes on the surface of silicon carbide fibers as hierarchical reinforcements. *RSC Adv.* 2016, 6, 14112–14119. [CrossRef]

94. ZHU, G.; XUE, Y.; HU, J.; YANG, J.; ZHOU, H.; GAO, L.; SHAN, Q.; DONG, S. Influence of boron nitride nanotubes on the damage evolution of SiC/SiC composites. *J. Eur. Ceram. Soc.* 2018, 38, 4614–4622. [CrossRef]
125. Tay, R.Y.; Li, H.; Tsang, S.H.; Jing, L.; Tan, D.; Wei, M.; Teo, E.H.T. Facile Synthesis of Millimeter-Scale Vertically Aligned Boron Nitride Nanotube Forests by Template-Assisted Chemical Vapor Deposition. Chem. Mater. 2015, 27, 7156–7163. [CrossRef]
126. Han, W.; Band, Y.; Kurashima, K.; Sato, T. Synthesis of boron nitride nanotubes from carbon nanotubes by a substitution reaction. Appl. Phys. Lett. 1998, 73, 3085–3087. [CrossRef]
127. Han, W.-Q.; Todd, P.J.; Strongin, M. Formation and growth mechanism of B10N nanotubes via a carbon nanotube–substitution reaction. Appl. Phys. Lett. 2006, 89, 173103. [CrossRef]
128. Golberg, D.; Band, Y.; Kurashima, K.; Sato, T. Ropes of BN multi-walled nanotubes. Solid State Commun. 2000, 116, 1–6. [CrossRef]
129. Zhong, B.; Song, L.; Huang, X.X.; Wen, G.W.; Xia, L. Synthesis of boron nitride nanotubes with SiC nanowire as template. Mater. Res. Bull. 2011, 46, 1521–1523. [CrossRef]
130. Kim, K.S.; Couillard, M.; Shin, H.; Plunkett, M.; Ruth, D.; Kingston, C.T.; Simard, B. Role of Hydrogen in High-Yield Growth of Boron Nitride Nanotubes at Atmospheric Pressure by Induction Thermal Plasma. ACS Nano 2018, 12, 884–893. [CrossRef]
131. Wang, L.; Li, T.; Ling, L.; Luo, J.; Zhang, K.; Xu, Y.; Lu, H.; Yao, Y. Remote catalysis for growth of boron nitride nanotubes by low pressure chemical vapor deposition. Chem. Phys. Lett. 2016, 652, 27–31. [CrossRef]
132. Ahmad, P.; Khandaker, M.U.; Khan, Z.R.; Amin, Y.M. Synthesis of boron nitride nanotubes via chemical vapour deposition: A comprehensive review. Rsc Adv. 2015, 5, 35116–35137. [CrossRef]
133. Chen, Z.-G.; Zou, J.; Li, F.; Liu, G.; Tang, D.-M.; Li, D.; Liu, C.; Ma, X.; Cheng, H.-M.; Lu, G.Q.; et al. Growth of Magnetic Yard-Glass Shaped Boron Nitride Nanotubes with Periodic Iron Nanoparticles. Adv. Funct. Mater. 2007, 17, 3371–3376. [CrossRef]
134. Wang, L.; Li, T.; Long, X.; Wang, X.; Xu, Y.; Yao, Y. Bimetallic catalytic growth of boron nitride nanotubes. Nanoscale 2017, 9, 1816–1819. [CrossRef] [PubMed]
135. Li, J.; Li, J.; Yin, Y.; Chen, Y.; Bi, X. Water-assisted chemical vapor deposition synthesis of boron nitride nanotubes and their photoluminescence property. Nanotechnology 2013, 24, 365605. [CrossRef]
136. Songfeng, E.; Long, X.; Li, C.; Geng, R.; Han, D.; Lu, W.; Yao, Y. Boron nitride nanotubes grown on stainless steel from a mixture of diboron trioxide and boron. Chem. Phys. Lett. 2017, 687, 307–311. [CrossRef]
137. Tang, D.-M.; Liu, C.; Cheng, H.-M. Controlled synthesis of quasi-one-dimensional boron nitride nanostructures. J. Mater. Res. 2007, 22, 2809–2816. [CrossRef]
138. Ma, R.; Band, Y.; Sato, T.; Kurashima, K. Thin boron nitride nanotubes with unusual large inner diameters. Chem. Phys. Lett. 2001, 350, 434–440. [CrossRef]
139. Pakdel, A.; Zhi, C.; Band, Y.; Nakayama, T.; Golberg, D. A comprehensive analysis of the CVD growth of boron nitride nanotubes. Nanotechnology 2012, 23, 215601. [CrossRef]
140. Wang, X.Z.; Wu, Q.; Hu, Z.; Chen, Y. Template-directed synthesis of boron nitride nanotube arrays by microwave plasma chemical reaction. Electrochim. Acta 2007, 52, 2841–2844. [CrossRef]
141. Su, C.-Y.; Chu, W.-Y.; Juang, Z.-Y.; Chen, K.-F.; Cheng, B.-M.; Chen, F.-R.; Tsai, C.-H. Large-Scale Synthesis of Boron Nitride Nanotubes with Iron-Supported Catalysts. J. Phys. Chem. C 2009, 113, 14732–14738. [CrossRef]
142. Kim, M.J.; Chatterjee, S.; Kim, S.M.; Stach, E.A.; Bradley, M.G.; Pender, M.J.; Sneddon, L.G.; Maruyama, B. Double-Walled Boron Nitride Nanotubes Grown by Floating Catalyst Chemical Vapor Deposition. Nano Lett. 2008, 8, 3298–3302. [CrossRef] [PubMed]
143. Ahmad, P.; Khandaker, M.U.; Amin, Y.M. Synthesis of boron nitride nanotubes by Argon supported Thermal Chemical Vapor Deposition. Phys. E Low-Dimens. Syst. Nanostruct. 2015, 67, 33–37. [CrossRef]
144. Xu, L.; Peng, Y.; Meng, Z.; Yu, W.; Zhang, S.; Liu, X.; Qian, Y. A Co-pyrolysis Method to Boron Nitride Nanotubes at Atmospheric Pressure by Induction Thermal Plasma. ACS Nano 2012, 6, 2841–2844. [CrossRef]
145. Dai, J.; Xu, L.; Fang, Z.; Sheng, D.; Guo, Q.; Ren, Z.; Wang, K.; Qian, Y. A convenient catalytic approach to synthesize straight boron nitride nanotubes using synergic nitrogen source. Chem. Phys. Lett. 2007, 440, 255–258. [CrossRef]
146. Gao, Z.; Zhi, C.; Band, Y.; Golberg, D.; Serizawa, T. Functionalization of boron nitride nanotubes for applications in nanobiomimetic. In Boron Nitride Nanotubes in Nanomedicine; Elsevier: Amsterdam, The Netherlands, 2016; pp. 17–40. [CrossRef]
147. Ribeiro, H.; von Cardoso Randow, P.; Vilela, D.N.; Adriane Luciano, M.; Maria de Andrade, L. Functionalized Boron Nitride Applications in Biotechnology. In Recent Advances in Boron-Containing Materials; IntechOpen: London, UK, 2020. [CrossRef]
148. Wang, Z.; Li, Q.; Liu, J.; Li, H.; Zheng, S. Covalent Surface Functionalization of Boron Nitride Nanotubes Fabricated with Diazonium Salt. J. Nanomater. 2018, 2018, 6717046. [CrossRef]
149. Gao, Z.; Zhi, C.; Band, Y.; Golberg, D.; Serizawa, T. Noncovalent Functionalization of Boron Nitride Nanotubes in Aqueous Media Opens Application Roads in Nanobiomimetic. Nanobiomimetic 2014, 4, 1. [CrossRef]
150. Zhi, C.Y.; Band, Y.; Golberg, D.; Serizawa, T. Isolation of Individual Boron Nitride Nanotubes via Peptide Wrapping. J. Am. Chem. Soc. 2010, 132, 4976–4977. [CrossRef]
154. Khalid, A.; Ahmad, P.; Khan, A.; Khandaker, M.U.; Kebaili, I.; Alam, M.M.; Din, I.U.; Muhammad, S.; Razzaq, Z.; Rehman, I.U.; et al. Cytotoxic and photocatalytic studies of hexagonal boron nitride nanotubes: A potential candidate for wastewater and air treatment. *RSC Adv.* **2022**, *12*, 6592–6600. [CrossRef] [PubMed]

155. Ciofani, G.; Danti, S. Evaluation of Cytocompatibility and Cell Response to Boron Nitride Nanotubes. In *Nanotechnology in Regenerative Medicine*; Humana Press: Totowa, NJ, USA, 2012; pp. 193–206. [CrossRef]

156. Ferreira, T.H.; Silva, P.R.O.; Santos, R.G.; Sousa, E.M.B. A Novel Synthesis Route to Produce Boron Nitride Nanotubes for Bioapplications. *J. Biomater. Nanobiotechnol.* **2011**, *2*, 426–434. [CrossRef]

157. Şen, Ö.; Emanet, M.; Çulha, M. Biocompatibility evaluation of boron nitride nanotubes. In *Boron Nitride Nanotubes in Nanomedicine*; Elsevier: Amsterdam, The Netherlands, 2016; pp. 41–58. [CrossRef]

158. Allard, C.; Schué, L.; Fossard, F.; Recher, G.; Nascimento, R.; Flahaut, E.; Loiseau, A.; Desjardins, P.; Martel, R.; Gaufrès, E. Confinement of Dyes inside Boron Nitride Nanotubes: Photostable and Shifted Fluorescence down to the Near Infrared. *Adv. Mater.* **2020**, *32*, 2001429. [CrossRef] [PubMed]